Secukinumab/Pediatric Psoriasis CAIN457A2310

AMNOG Dossier Sensitivity Analysis A

Date: 24.08.2020

Document Status: Final

Author: Monika Schwager, Winicker Norimed GmbH

Table of Contents

Tables

Patient Disposition and Baseline Characteristics

1.1 Patient Disposition and Compliance (RAN, FAS)

Disposition/Reason	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Randomized (RAN)	**56 (100.0)**	**58 (100.0)**	**41 (100.0)**	**155 (100.0)**
Full Analysis Set (FAS)	**56 (100.0)**	**58 (100.0)**	**41 (100.0)**	**155 (100.0)**
Study discontinuation during induction period	**1 (1.8)**	**2 (3.4)**	**0 (0.0)**	**3 (1.9)**
Reasons for study discontinuation during induction period				
Adverse event	0 (0.0)	1 (1.7)	0 (0.0)	1 (0.6)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	1 (1.8)	1 (1.7)	0 (0.0)	2 (1.3)
Study discontinuation during maintenance period	**0 (0.0)**	**1 (1.7)**	**2 (4.9)**	**3 (1.9)**
Reasons for study discontinuation during maintenance period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.6)
Protocol deviation	0 (0.0)	1 (1.7)	1 (2.4)	2 (1.3)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study drug during induction period				
Received study drug	56 (100.0)	58 (100.0)	41 (100.0)	155 (100.0)
Did not receive study drug	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Completed induction period on double-blind study drug	55 (98.2)	56 (96.6)	40 (97.6)	151 (97.4)
Prematurely discontinued double-blind study drug during induction period	1 (1.8)	2 (3.4)	1 (2.4)	4 (2.6)
Primary reason for premature discontinuation from double-blind study drug during induction period				
Adverse event	0 (0.0)	1 (1.7)	0 (0.0)	1 (0.6)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.6)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	1 (1.8)	1 (1.7)	0 (0.0)	2 (1.3)

Disposition/Reason	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Study drug during maintenance period				
Received study drug	55 (98.2)	56 (96.6)	40 (97.6)	151 (97.4)
Did not receive study drug	1 (1.8)	2 (3.4)	1 (2.4)	4 (2.6)
Completed maintenance period on double-blind study drug	53 (94.6)	53 (91.4)	34 (82.9)	140 (90.3)
Prematurely discontinued double-blind study drug during maintenance period	2 (3.6)	3 (5.2)	6 (14.6)	11 (7.1)
Primary reason for premature discontinuation from double-blind study drug during maintenance period				
Adverse event	2 (3.6)	0 (0.0)	1 (2.4)	3 (1.9)
Lack of efficacy	0 (0.0)	1 (1.7)	3 (7.3)	4 (2.6)
Pregnancy	0 (0.0)	0 (0.0)	1 (2.4)	1 (0.6)
Protocol deviation	0 (0.0)	2 (3.4)	1 (2.4)	3 (1.9)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviations during induction period				
Subject with at least one protocol deviation	14 (25.0)	17 (29.3)	18 (43.9)	49 (31.6)
Selection criteria not met	0 (0.0)	2 (3.4)	0 (0.0)	2 (1.3)
Treatment deviation	1 (1.8)	2 (3.4)	7 (17.1)	10 (6.5)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	13 (23.2)	15 (25.9)	11 (26.8)	39 (25.2)
Protocol deviations during maintenance period				
Subject with at least one protocol deviation	19 (33.9)	20 (34.5)	21 (51.2)	60 (38.7)
Selection criteria not met	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	12 (21.4)	12 (20.7)	16 (39.0)	40 (25.8)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	2 (4.9)	2 (1.3)
Other deviation	10 (17.9)	10 (17.2)	6 (14.6)	26 (16.8)

1.2 Length of Study Participation (FAS)

Subgroups	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Study participation in induction period				
Mean ± SD (in days)	86.2 ± 13.4	87.0 ± 17.0	87.3 ± 8.8	86.8 ± 13.8
Median (in days)	85.0	85.0	85.0	85.0
Range (in days)	9 - 137	15 - 176	78 - 134	9 - 176
Study participation in maintenance period				
Mean ± SD (in days)	273.4 ± 35.6	277.3 ± 31.6	253.7 ± 76.3	269.6 ± 49.3
Median (in days)	281.0	281.0	281.0	281.0
Range (in days)	42 - 309	64 - 316	24 - 305	24 - 316
Study participation in induction+maintenance period				
Mean ± SD (in days)	353.7 ± 58.5	353.7 ± 60.2	333.8 ± 83.3	348.4 ± 66.7
Median (in days)	365.0	365.0	365.0	365.0
Range (in days)	9 - 393	15 - 401	85 - 394	9 - 401

Duration of study participation in each period is defined as the time from the first entry up to the last entry in the respective period.

1.3 Characterization of Study Population, Demographic Characteristics (FAS)

Patient characteristics	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Age (years)				
Mean ± SD	13.6 ± 3.0	13.5 ± 3.2	13.5 ± 2.9	13.5 ± 3.1
Median	14.0	14.5	14.0	14.0
Range	7 - 17	6 - 17	6 - 17	6 - 17
Age group (years), n(%)				
<12	13 (23.2)	12 (20.7)	10 (24.4)	35 (22.6)
≥12	43 (76.8)	46 (79.3)	31 (75.6)	120 (77.4)
Sex, n(%)				
Male	20 (35.7)	27 (46.6)	16 (39.0)	63 (40.6)
Female	36 (64.3)	31 (53.4)	25 (61.0)	92 (59.4)
Weight (kg)				
Mean ± SD	52.3 ± 16.2	55.9 ± 22.6	52.0 ± 19.4	53.6 ± 19.6
Median	50.1	51.7	50.0	50.5
Range	21 - 88.9	17.6 - 116	20.5 - 105.5	17.6 - 116
Weight group (kg), n(%)				
<25	4 (7.1)	4 (6.9)	4 (9.8)	12 (7.7)
≥25 - <50	24 (42.9)	22 (37.9)	16 (39.0)	62 (40.0)
≥50	28 (50.0)	32 (55.2)	21 (51.2)	81 (52.3)
Height (cm)				
Mean ± SD	158.1 ± 15.5	156.2 ± 18.3	154.6 ± 16.5	156.4 ± 16.8
Median	160.0	159.0	158.0	160.0
Range	121 - 185	115 - 194	118 - 183	115 - 194
BMI (kg/m)				
Mean ± SD	20.4 ± 3.8	22.1 ± 5.8	21.0 ± 4.8	21.2 ± 4.9
Median	19.5	21.3	21.0	20.5
Range	14.1 - 30.7	11.1 - 42.5	13.7 - 31.5	11.1 - 42.5
Child bearing status, n(%)				
Able to bear children	23 (41.1)	23 (39.7)	16 (39.0)	62 (40.0)
Premenarche	13 (23.2)	8 (13.8)	9 (22.0)	30 (19.4)
Race, n(%)				
Caucasian	47 (83.9)	50 (86.2)	30 (73.2)	127 (81.9)
Black	1 (1.8)	1 (1.7)	0 (0.0)	2 (1.3)
Asian	2 (3.6)	2 (3.4)	3 (7.3)	7 (4.5)
Native American	5 (8.9)	4 (6.9)	8 (19.5)	17 (11.0)
Other	1 (1.8)	1 (1.7)	0 (0.0)	2 (1.3)

Patient characteristics	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Ethnicity, n(%)				
Hispanic/Latino	6 (10.7)	6 (10.3)	9 (22.0)	21 (13.5)
Not Hispanic or Latino	43 (76.8)	43 (74.1)	27 (65.9)	113 (72.9)
Unknown	4 (7.1)	3 (5.2)	2 (4.9)	9 (5.8)
Region, n(%)				
Africa	3 (5.4)	3 (5.2)	4 (9.8)	10 (6.5)
America	6 (10.7)	7 (12.1)	8 (19.5)	21 (13.5)
Asia	8 (14.3)	2 (3.4)	5 (12.2)	15 (9.7)
Europe	39 (69.6)	46 (79.3)	24 (58.5)	109 (70.3)

1.4 Disease History and Prior Medication (FAS)

	Treatment Groups			
Disease history	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Diagnosis of plaque-type psoriasis, n(%)				
Yes	56 (100.0)	58 (100.0)	41 (100.0)	155 (100.0)
Time since first diagnosis of plaque-type psoriasis (years)				
Mean ± SD	4.9 ± 4.4	5.9 ± 5.0	4.5 ± 3.7	5.2 ± 4.5
Median	3.8	4.1	3.9	3.9
Range	0.3 - 17.0	0.4 - 17.5	0.3 - 14.0	0.3 - 17.5
Diagnosis of psoriatic arthritis, n(%)				
Yes	6 (10.7)	5 (8.6)	3 (7.3)	14 (9.0)
No	50 (89.3)	53 (91.4)	38 (92.7)	141 (91.0)
Time since first diagnosis of psoriatic arthritis (years)				
Mean ± SD	4.0 ± 3.6	2.4 ± 2.5	1.4 ± 1.1	2.9 ± 2.9
Median	2.8	0.8	1.2	1.9
Range	0.1 - 9.7	0.5 - 5.9	0.3 - 2.6	0.1 - 9.7
Previous psoriasis therapies, n(%)				
Yes	56 (100.0)	58 (100.0)	41 (100.0)	155 (100.0)
Previous systemic therapies, n(%)				
Yes	33 (58.9)	32 (55.2)	19 (46.3)	84 (54.2)
No	23 (41.1)	26 (44.8)	22 (53.7)	71 (45.8)
Failure	30 (53.6)	27 (46.6)	14 (34.1)	71 (45.8)
no failure	3 (5.4)	5 (8.6)	5 (12.2)	13 (8.4)
Previous phototherapy or photochemotherapy, n(%)				
Yes	22 (39.3)	36 (62.1)	21 (51.2)	79 (51.0)
No	34 (60.7)	22 (37.9)	20 (48.8)	76 (49.0)
Failure	18 (32.1)	27 (46.6)	18 (43.9)	63 (40.6)
no failure	4 (7.1)	9 (15.5)	3 (7.3)	16 (10.3)
Previous topical therapy, n(%)				
Yes	46 (82.1)	54 (93.1)	38 (92.7)	138 (89.0)
No	10 (17.9)	4 (6.9)	3 (7.3)	17 (11.0)
Failure	41 (73.2)	48 (82.8)	31 (75.6)	120 (77.4)
no failure	5 (8.9)	6 (10.3)	7 (17.1)	18 (11.6)

	Treatment Groups			
Disease history	**SEC low (N=56)**	**SEC high (N=58)**	**ETA (N=41)**	**Total (N=155)**
Failure of at least one systemic therapy or phototherapy or photochemotherapy, n(%)				
Yes	39 (69.6)	42 (72.4)	26 (63.4)	107 (69.0)

1.5 Baseline Disease Characteristics (FAS)

Baseline disease characteristics	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Baseline PASI score				
Mean ± SD	28.2 ± 7.4	27.2 ± 7.8	28.4 ± 9.1	27.9 ± 8.0
Median	26.0	25.5	24.8	25.2
Range	20.2 - 48	17.2 - 58.8	20.1 - 59.8	17.2 - 59.8
Baseline PASI, n(%)				
≤20	0 (0.0)	1 (1.7)	0 (0.0)	1 (0.6)
>20	56 (100.0)	57 (98.3)	41 (100.0)	154 (99.4)
Baseline total BSA				
Mean ± SD	38.7 ± 15.9	38.6 ± 16.5	43.1 ± 19.6	39.8 ± 17.2
Median	36.4	35.3	37.7	36.0
Range	12 - 72.5	16 - 94	13.1 - 90.5	12 - 94
Baseline IGA mod 2011 score, n(%)				
3 = Moderate disease	0 (0.0)	1 (1.7)	0 (0.0)	1 (0.6)
4 = Severe disease	56 (100.0)	57 (98.3)	41 (100.0)	154 (99.4)

1.6 Subgroups (FAS)

	Treatment Groups			
Subgroups	**SEC low (N=56)**	**SEC high (N=58)**	**ETA (N=41)**	**Total (N=155)**
Subgroup Age, n (%)				
< 12 years	13 (23.2)	12 (20.7)	10 (24.4)	35 (22.6)
≥ 12 years	43 (76.8)	46 (79.3)	31 (75.6)	120 (77.4)
Subgroup Gender, n (%)				
Male	20 (35.7)	27 (46.6)	16 (39.0)	63 (40.6)
Female	36 (64.3)	31 (53.4)	25 (61.0)	92 (59.4)
Subgroup Disease Severity, n (%)				
Baseline PASI ≤ median	27 (48.2)	29 (50.0)	22 (53.7)	78 (50.3)
Baseline PASI > median	29 (51.8)	29 (50.0)	19 (46.3)	77 (49.7)
Subgroup Region, n (%)				
Africa	3 (5.4)	3 (5.2)	4 (9.8)	10 (6.5)
America	6 (10.7)	7 (12.1)	8 (19.5)	21 (13.5)
Asia	8 (14.3)	2 (3.4)	5 (12.2)	15 (9.7)
Europe	39 (69.6)	46 (79.3)	24 (58.5)	109 (70.3)
Subgroup Region - Europe vs. Others, n (%)				
Europe	39 (69.6)	46 (79.3)	24 (58.5)	109 (70.3)
Others	17 (30.4)	12 (20.7)	17 (41.5)	46 (29.7)
Subgroup Weight, n (%)				
< 25 kg	4 (7.1)	4 (6.9)	4 (9.8)	12 (7.7)
≥ 25 kg - < 50 kg	24 (42.9)	22 (37.9)	16 (39.0)	62 (40.0)
≥ 50 kg	28 (50.0)	32 (55.2)	21 (51.2)	81 (52.3)
Subgroup Weight - < 50kg vs. ≥ 50 kg, n (%)				
< 50 kg	28 (50.0)	26 (44.8)	20 (48.8)	74 (47.7)
≥ 50 kg	28 (50.0)	32 (55.2)	21 (51.2)	81 (52.3)
Subgroup Previous Systemic Therapy, n (%)				
No	23 (41.1)	26 (44.8)	22 (53.7)	71 (45.8)
Yes	33 (58.9)	32 (55.2)	19 (46.3)	84 (54.2)
Efficacy and safety subgroup analysis is displayed for all subgrouping factors with at least 10 patients in each subgroup.				

Efficacy Analysis

2.1 All-Cause Mortality (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
All-cause Mortality						
N'	**56**	**58**	**41**			
n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

3.0 BSA (Percent), Return Rates (FAS)

	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Number of patients with valid data n (%)				
Baseline Returns	56 (100.0)	58 (100.0)	41 (100.0)	155 (100.0)
Week 1 Returns	53 (94.6)	54 (93.1)	41 (100.0)	148 (95.5)
Week 2 Returns	51 (91.1)	55 (94.8)	39 (95.1)	145 (93.5)
Week 3 Returns	55 (98.2)	53 (91.4)	41 (100.0)	149 (96.1)
Week 4 Returns	54 (96.4)	56 (96.6)	38 (92.7)	148 (95.5)
Week 8 Returns	55 (98.2)	55 (94.8)	41 (100.0)	151 (97.4)
Week 12 Returns	45 (80.4)	53 (91.4)	35 (85.4)	133 (85.8)
Week 13 Returns	42 (75.0)	50 (86.2)	31 (75.6)	123 (79.4)
Week 14 Returns	48 (85.7)	52 (89.7)	34 (82.9)	134 (86.5)
Week 15 Returns	52 (92.9)	49 (84.5)	34 (82.9)	135 (87.1)
Week 16 Returns	53 (94.6)	54 (93.1)	36 (87.8)	143 (92.3)
Week 20 Returns	55 (98.2)	55 (94.8)	38 (92.7)	148 (95.5)
Week 24 Returns	55 (98.2)	54 (93.1)	37 (90.2)	146 (94.2)
Week 28 Returns	54 (96.4)	53 (91.4)	36 (87.8)	143 (92.3)
Week 32 Returns	55 (98.2)	52 (89.7)	36 (87.8)	143 (92.3)
Week 36 Returns	54 (96.4)	54 (93.1)	35 (85.4)	143 (92.3)
Week 40 Returns	53 (94.6)	55 (94.8)	35 (85.4)	143 (92.3)
Week 44 Returns	54 (96.4)	55 (94.8)	33 (80.5)	142 (91.6)
Week 48 Returns	53 (94.6)	51 (87.9)	34 (82.9)	138 (89.0)
Week 52 Returns	54 (96.4)	55 (94.8)	34 (82.9)	143 (92.3)

3.1 BSA (Percent), Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
N'	55	57	41		
Baseline Mean (SD)	38.75 (15.94)	38.56 (16.52)	43.13 (19.56)		
Week 52 Adjusted Mean Change (SE)	-35.14 (1.85)	-34.22 (1.83)	-31.34 (2.25)	-3.79 [-9.51; 1.93] 0.194	-2.88 [-8.58; 2.82] 0.322

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

3.2 BSA (Percent), Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.093					
Age < 12 years, N	**13**	**12**	**10**		
N'	13	12	10		
Baseline Mean (SD)	45.37 (18.34)	40.01 (15.80)	51.31 (18.96)		
Week 52 Adjusted Mean Change (SE)	-37.81 (3.76)	-32.89 (4.03)	-35.07 (4.44)	-2.74 [-14.09; 8.61] 0.636	2.18 [-9.57; 13.92] 0.716
Age ≥ 12 years, N	**43**	**46**	**31**		
N'	42	45	31		
Baseline Mean (SD)	36.75 (14.80)	38.18 (16.85)	40.49 (19.30)		
Week 52 Adjusted Mean Change (SE)	-34.25 (2.11)	-34.57 (2.03)	-30.07 (2.57)	-4.18 [-10.70; 2.35] 0.210	-4.49 [-10.92; 1.93] 0.170

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.3 BSA (Percent), Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.591					
Male, N	**20**	**27**	**16**		
N'	20	27	16		
Baseline Mean (SD)	39.27 (18.48)	37.35 (17.01)	41.99 (18.95)		
Week 52 Adjusted Mean Change (SE)	-35.54 (3.07)	-35.61 (2.67)	-31.37 (3.71)	-4.17 [-13.62; 5.27] 0.386	-4.24 [-13.21; 4.73] 0.354
Female, N	**36**	**31**	**25**		
N'	35	30	25		
Baseline Mean (SD)	38.46 (14.62)	39.62 (16.29)	43.86 (20.29)		
Week 52 Adjusted Mean Change (SE)	-34.88 (2.34)	-32.98 (2.54)	-31.23 (2.85)	-3.65 [-10.89; 3.59] 0.323	-1.75 [-9.24; 5.73] 0.646

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.4 BSA (Percent), Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.818					
Baseline PASI ≤ Median, N	**27**	**29**	**22**		
N'	27	28	22		
Baseline Mean (SD)	27.47 (9.03)	34.28 (13.49)	33.30 (13.05)		
Week 52 Adjusted Mean Change (SE)	-30.92 (2.68)	-32.02 (2.57)	-29.93 (3.01)	-0.99 [-8.79; 6.81] 0.804	-2.09 [-9.80; 5.62] 0.596
Baseline PASI > Median, N	**29**	**29**	**19**		
N'	28	29	19		
Baseline Mean (SD)	49.25 (13.66)	42.85 (18.32)	54.52 (19.91)		
Week 52 Adjusted Mean Change (SE)	-39.32 (2.63)	-36.51 (2.57)	-33.33 (3.42)	-5.99 [-14.23; 2.24] 0.154	-3.18 [-11.47; 5.12] 0.453

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.5 BSA (Percent), Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.173					
Europe, N	**39**	**46**	**24**		
N'	39	46	24		
Baseline Mean (SD)	37.35 (15.33)	37.88 (16.48)	36.53 (16.13)		
Week 52 Adjusted Mean Change (SE)	-35.65 (2.17)	-35.41 (2.01)	-34.99 (2.85)	-0.66 [-7.68; 6.36] 0.853	-0.43 [-7.26; 6.41] 0.903
Others, N	**17**	**12**	**17**		
N'	16	11	17		
Baseline Mean (SD)	41.95 (17.33)	41.16 (17.14)	52.45 (20.60)		
Week 52 Adjusted Mean Change (SE)	-33.99 (3.36)	-29.55 (4.05)	-25.87 (3.58)	-8.12 [-17.73; 1.49] 0.098	-3.68 [-14.28; 6.92] 0.496

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.6 BSA (Percent), Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.852					
Weight < 50 kg, N	28	26	20		
N'	28	25	20		
Baseline Mean (SD)	39.88 (16.54)	39.46 (18.18)	47.16 (17.88)		
Week 52 Adjusted Mean Change (SE)	-35.58 (2.55)	-31.50 (2.74)	-30.68 (3.18)	-4.90 [-12.89; 3.09] 0.229	-0.82 [-9.05; 7.42] 0.846
Weight ≥ 50 kg, N	28	32	21		
N'	27	32	21		
Baseline Mean (SD)	37.61 (15.54)	37.83 (15.30)	39.30 (20.73)		
Week 52 Adjusted Mean Change (SE)	-34.56 (2.63)	-36.28 (2.41)	-31.86 (3.12)	-2.71 [-10.71; 5.29] 0.507	-4.43 [-12.16; 3.30] 0.261

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.7 BSA (Percent), Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.398					
No previous systemic therapy, N	**23**	**26**	**22**		
N'	22	25	22		
Baseline Mean (SD)	42.17 (18.95)	33.22 (13.21)	43.07 (17.26)		
Week 52 Adjusted Mean Change (SE)	-36.47 (2.95)	-34.14 (2.79)	-33.83 (3.03)	-2.64 [-10.93; 5.65] 0.532	-0.31 [-8.43; 7.81] 0.941
Previous systemic therapy, N	**33**	**32**	**19**		
N'	33	32	19		
Baseline Mean (SD)	36.36 (13.26)	42.91 (17.82)	43.21 (22.41)		
Week 52 Adjusted Mean Change (SE)	-34.31 (2.38)	-34.28 (2.44)	-28.25 (3.35)	-6.06 [-14.13; 2.01] 0.141	-6.03 [-14.14; 2.08] 0.145

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

4.1 BSA 0% (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
N'	54	55	34			
n (%)	26.25 (46.88)	29.72 (51.24)	9.07 (22.12)			
SEC low vs. ETA				3.07 [1.24; 7.59] 0.015	2.12 [1.12; 4.03] 0.022	0.25 [0.06; 0.43] 0.008
SEC high vs. ETA				3.65 [1.48; 9.00] 0.005	2.32 [1.23; 4.35] 0.009	0.29 [0.11; 0.47] 0.002

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.2 BSA 0% by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.186**					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	9.00 (69.23)	5.37 (44.75)	4.01 (40.10)			
SEC low vs. ETA				3.18 [0.59; 17.12] 0.179	1.73 [0.74; 4.00] 0.203	0.29 [-0.10; 0.69] 0.148
SEC high vs. ETA				1.20 [0.22; 6.53] 0.834	1.11 [0.41; 3.04] 0.836	0.05 [-0.38; 0.47] 0.829
Age ≥ 12 years, N / N'	**43 / 41**	**46 / 44**	**31 / 25**			
n (%)	17.25 (40.12)	24.35 (52.93)	5.06 (16.32)			
SEC low vs. ETA				3.38 [1.09; 10.48] 0.035	2.46 [1.02; 5.95] 0.046	0.24 [0.04; 0.44] 0.018
SEC high vs. ETA				5.64 [1.85; 17.21] 0.002	3.25 [1.39; 7.58] 0.007	0.37 [0.17; 0.56] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.3 BSA 0% by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.954**					
Male, N / N'	**20 / 20**	**27 / 26**	**16 / 12**			
n (%)	8.00 (40.00)	13.13 (48.63)	3.01 (18.81)			
SEC low vs. ETA				2.80 [0.61; 12.79] 0.185	2.13 [0.67; 6.74] 0.199	0.21 [-0.08; 0.50] 0.149
SEC high vs. ETA				3.96 [0.93; 16.90] 0.063	2.59 [0.87; 7.71] 0.088	0.30 [0.03; 0.57] 0.031
Female, N / N'	**36 / 34**	**31 / 29**	**25 / 22**			
n (%)	18.25 (50.69)	16.59 (53.52)	6.06 (24.24)			
SEC low vs. ETA				3.15 [1.03; 9.69] 0.045	2.09 [0.97; 4.52] 0.060	0.26 [0.03; 0.50] 0.028
SEC high vs. ETA				3.52 [1.10; 11.19] 0.033	2.21 [1.02; 4.79] 0.045	0.29 [0.05; 0.54] 0.020

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.4 BSA 0% by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	p=0.320					
Baseline PASI ≤ Median, N / N'	27 / 27	29 / 28	22 / 19			
n (%)	13.00 (48.15)	16.22 (55.93)	3.06 (13.91)			
SEC low vs. ETA				5.56 [1.34; 22.98] 0.018	3.47 [1.13; 10.65] 0.030	0.34 [0.10; 0.58] 0.005
SEC high vs. ETA				7.55 [1.84; 30.95] 0.005	4.03 [1.34; 12.11] 0.013	0.42 [0.19; 0.65] <.001
Baseline PASI > Median, N / N'	29 / 27	29 / 27	19 / 15			
n (%)	13.25 (45.69)	13.50 (46.55)	6.01 (31.63)			
SEC low vs. ETA				1.80 [0.54; 6.00] 0.341	1.44 [0.67; 3.13] 0.353	0.14 [-0.14; 0.42] 0.323
SEC high vs. ETA				1.86 [0.55; 6.23] 0.316	1.47 [0.68; 3.19] 0.328	0.15 [-0.13; 0.43] 0.296

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.5 BSA 0% by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.524**					
Europe, N / N'	**39 / 38**	**46 / 44**	**24 / 21**			
n (%)	23.00 (58.97)	28.50 (61.96)	7.05 (29.37)			
SEC low vs. ETA				3.39 [1.15; 9.97] 0.027	2.01 [1.02; 3.95] 0.043	0.30 [0.06; 0.54] 0.015
SEC high vs. ETA				3.84 [1.33; 11.08] 0.013	2.11 [1.09; 4.10] 0.028	0.33 [0.09; 0.56] 0.006
Others, N / N'	**17 / 16**	**12 / 11**	**17 / 13**			
n (%)	3.25 (19.12)	1.22 (10.17)	2.02 (11.88)			
SEC low vs. ETA				1.71 [0.25; 11.59] 0.580	1.60 [0.31; 8.36] 0.578	0.07 [-0.18; 0.32] 0.567
SEC high vs. ETA				0.81 [0.07; 9.64] 0.867	0.82 [0.09; 7.84] 0.862	-0.02 [-0.26; 0.22] 0.888

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.6 BSA 0% by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.012**					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 24**	**20 / 17**			
n (%)	17.00 (60.71)	9.59 (36.88)	6.02 (30.10)			
SEC low vs. ETA				3.49 [1.04; 11.66] 0.042	2.02 [0.97; 4.20] 0.060	0.31 [0.04; 0.58] 0.027
SEC high vs. ETA				1.35 [0.39; 4.69] 0.640	1.22 [0.52; 2.86] 0.641	0.07 [-0.21; 0.35] 0.632
Weight ≥ 50 kg, N / N'	**28 / 26**	**32 / 31**	**21 / 17**			
n (%)	9.25 (33.04)	20.13 (62.91)	3.05 (14.52)			
SEC low vs. ETA				2.85 [0.67; 12.11] 0.157	2.28 [0.70; 7.38] 0.170	0.19 [-0.05; 0.42] 0.119
SEC high vs. ETA				9.54 [2.34; 38.87] 0.002	4.34 [1.47; 12.79] 0.008	0.48 [0.26; 0.71] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.7 BSA 0% by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.154**					
No previous systemic therapy, N / N'	**23 / 21**	**26 / 24**	**22 / 19**			
n (%)	14.25 (61.96)	13.59 (52.27)	8.01 (36.41)			
SEC low vs. ETA				2.78 [0.83; 9.28] 0.097	1.70 [0.90; 3.23] 0.105	0.26 [-0.03; 0.54] 0.079
SEC high vs. ETA				1.89 [0.59; 6.04] 0.285	1.43 [0.73; 2.80] 0.291	0.16 [-0.12; 0.44] 0.270
Previous systemic therapy, N / N'	**33 / 33**	**32 / 31**	**19 / 15**			
n (%)	12.00 (36.36)	16.13 (50.41)	1.06 (5.58)			
SEC low vs. ETA				9.49 [1.13; 79.56] 0.038	6.63 [0.94; 46.96] 0.058	0.31 [0.11; 0.50] 0.002
SEC high vs. ETA				16.65 [2.00; 138.75] 0.009	9.19 [1.32; 63.68] 0.025	0.45 [0.24; 0.65] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

5.0 PASI, Return Rates (FAS)

	Treatment Groups			
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	Total (N=155)
Number of patients with valid data n (%)				
Baseline Returns	56 (100.0)	58 (100.0)	41 (100.0)	155 (100.0)
Week 1 Returns	53 (94.6)	54 (93.1)	41 (100.0)	148 (95.5)
Week 2 Returns	51 (91.1)	55 (94.8)	39 (95.1)	145 (93.5)
Week 3 Returns	55 (98.2)	53 (91.4)	41 (100.0)	149 (96.1)
Week 4 Returns	54 (96.4)	56 (96.6)	38 (92.7)	148 (95.5)
Week 8 Returns	55 (98.2)	55 (94.8)	41 (100.0)	151 (97.4)
Week 12 Returns	45 (80.4)	53 (91.4)	35 (85.4)	133 (85.8)
Week 13 Returns	42 (75.0)	50 (86.2)	31 (75.6)	123 (79.4)
Week 14 Returns	48 (85.7)	52 (89.7)	34 (82.9)	134 (86.5)
Week 15 Returns	52 (92.9)	49 (84.5)	34 (82.9)	135 (87.1)
Week 16 Returns	53 (94.6)	54 (93.1)	36 (87.8)	143 (92.3)
Week 20 Returns	55 (98.2)	55 (94.8)	38 (92.7)	148 (95.5)
Week 24 Returns	55 (98.2)	54 (93.1)	37 (90.2)	146 (94.2)
Week 28 Returns	54 (96.4)	53 (91.4)	36 (87.8)	143 (92.3)
Week 32 Returns	55 (98.2)	52 (89.7)	36 (87.8)	143 (92.3)
Week 36 Returns	54 (96.4)	54 (93.1)	35 (85.4)	143 (92.3)
Week 40 Returns	53 (94.6)	55 (94.8)	35 (85.4)	143 (92.3)
Week 44 Returns	54 (96.4)	55 (94.8)	33 (80.5)	142 (91.6)
Week 48 Returns	53 (94.6)	51 (87.9)	34 (82.9)	138 (89.0)
Week 52 Returns	54 (96.4)	55 (94.8)	34 (82.9)	143 (92.3)

5.1 PASI, Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
N'	55	57	41		
Baseline Mean (SD)	28.21 (7.37)	27.23 (7.83)	28.40 (9.05)		
Week 52 Adjusted Mean Change (SE)	-25.96 (1.09)	-25.86 (1.08)	-21.95 (1.32)	-4.01 [-7.37; -0.65] 0.019	-3.90 [-7.25; -0.55] 0.022

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

5.2 PASI, Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.281					
Age < 12 years, N	**13**	**12**	**10**		
N'	13	12	10		
Baseline Mean (SD)	32.33 (9.81)	26.91 (5.98)	29.88 (9.00)		
Week 52 Adjusted Mean Change (SE)	-27.62 (2.21)	-23.97 (2.35)	-21.45 (2.57)	-6.16 [-12.79; 0.46] 0.068	-2.51 [-9.36; 4.33] 0.472
Age ≥ 12 years, N	**43**	**46**	**31**		
N'	42	45	31		
Baseline Mean (SD)	26.97 (6.06)	27.32 (8.30)	27.93 (9.17)		
Week 52 Adjusted Mean Change (SE)	-25.40 (1.23)	-26.34 (1.18)	-22.10 (1.50)	-3.31 [-7.11; 0.50] 0.089	-4.24 [-8.00; -0.49] 0.027

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.3 PASI, Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.638					
Male, N	**20**	**27**	**16**		
N'	20	27	16		
Baseline Mean (SD)	27.76 (7.66)	28.09 (7.96)	28.79 (9.26)		
Week 52 Adjusted Mean Change (SE)	-25.42 (1.81)	-26.70 (1.57)	-22.60 (2.19)	-2.81 [-8.39; 2.76] 0.322	-4.09 [-9.39; 1.20] 0.129
Female, N	**36**	**31**	**25**		
N'	35	30	25		
Baseline Mean (SD)	28.46 (7.30)	26.49 (7.77)	28.16 (9.11)		
Week 52 Adjusted Mean Change (SE)	-26.27 (1.38)	-25.11 (1.50)	-21.61 (1.68)	-4.66 [-8.91; -0.41] 0.032	-3.50 [-7.90; 0.91] 0.120

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.4 PASI, Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.208					
Baseline PASI ≤ Median, N	27	29	22		
N'	27	28	22		
Baseline Mean (SD)	22.48 (1.68)	22.51 (1.81)	22.63 (1.55)		
Week 52 Adjusted Mean Change (SE)	-24.21 (1.59)	-23.90 (1.56)	-22.26 (1.81)	-1.95 [-6.53; 2.63] 0.404	-1.64 [-6.19; 2.90] 0.478
Baseline PASI > Median, N	29	29	19		
N'	28	29	19		
Baseline Mean (SD)	33.55 (6.54)	31.96 (8.68)	35.09 (9.57)		
Week 52 Adjusted Mean Change (SE)	-27.75 (1.59)	-27.84 (1.55)	-21.66 (2.04)	-6.09 [-10.94; -1.25] 0.014	-6.18 [-11.04; -1.32] 0.013

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.5 PASI, Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.095					
Europe, N	**39**	**46**	**24**		
N'	39	46	24		
Baseline Mean (SD)	28.11 (7.94)	27.83 (8.51)	27.26 (8.92)		
Week 52 Adjusted Mean Change (SE)	-26.17 (1.28)	-26.65 (1.19)	-24.95 (1.68)	-1.22 [-5.36; 2.92] 0.564	-1.70 [-5.74; 2.33] 0.408
Others, N	**17**	**12**	**17**		
N'	16	11	17		
Baseline Mean (SD)	28.45 (6.05)	24.95 (3.86)	30.02 (9.26)		
Week 52 Adjusted Mean Change (SE)	-25.47 (1.98)	-22.65 (2.39)	-17.44 (2.08)	-8.04 [-13.67; -2.40] 0.005	-5.21 [-11.44; 1.02] 0.101

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.6 PASI, Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.936					
Weight < 50 kg, N	28	26	20		
N'	28	25	20		
Baseline Mean (SD)	29.19 (8.33)	26.17 (8.25)	29.29 (8.79)		
Week 52 Adjusted Mean Change (SE)	-26.54 (1.49)	-24.19 (1.61)	-20.32 (1.85)	-6.23 [-10.88; -1.57] 0.009	-3.87 [-8.68; 0.94] 0.115
Weight ≥ 50 kg, N	28	32	21		
N'	27	32	21		
Baseline Mean (SD)	27.23 (6.26)	28.10 (7.50)	27.56 (9.44)		
Week 52 Adjusted Mean Change (SE)	-25.27 (1.54)	-27.12 (1.41)	-23.50 (1.83)	-1.77 [-6.46; 2.91] 0.459	-3.61 [-8.14; 0.92] 0.118

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.7 PASI, Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.221					
No previous systemic therapy, N	**23**	**26**	**22**		
N'	22	25	22		
Baseline Mean (SD)	28.52 (7.68)	25.00 (4.55)	27.70 (6.81)		
Week 52 Adjusted Mean Change (SE)	-26.50 (1.74)	-25.99 (1.64)	-23.73 (1.79)	-2.77 [-7.65; 2.11] 0.266	-2.26 [-7.01; 2.49] 0.351
Previous systemic therapy, N	**33**	**32**	**19**		
N'	33	32	19		
Baseline Mean (SD)	28.00 (7.25)	29.05 (9.41)	29.23 (11.26)		
Week 52 Adjusted Mean Change (SE)	-25.63 (1.40)	-25.76 (1.43)	-19.76 (1.98)	-5.87 [-10.62; -1.12] 0.015	-5.99 [-10.78; -1.21] 0.014

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

6.1 PASI Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
N'	**54**	**55**	**34**			
n (%)	55.83 (99.70)	56.83 (97.98)	35.96 (87.71)			
SEC low vs. ETA				9.41 [N.E.; N.E.] N.E.	1.14 [1.00; 1.30] 0.053	0.12 [0.01; 0.23] 0.039
SEC high vs. ETA				6.81 [0.72; 64.17] 0.094	1.12 [0.98; 1.28] 0.109	0.10 [-0.02; 0.22] 0.093
PASI75 Response Week 52						
N'	**54**	**55**	**34**			
n (%)	50.37 (89.95)	54.19 (93.43)	29.96 (73.07)			
SEC low vs. ETA				3.26 [1.02; 10.39] 0.046	1.23 [0.99; 1.53] 0.063	0.17 [0.00; 0.34] 0.047
SEC high vs. ETA				5.25 [1.33; 20.66] 0.018	1.28 [1.03; 1.59] 0.024	0.20 [0.04; 0.37] 0.014
PASI90 Response Week 52						
N'	**54**	**55**	**34**			
n (%)	43.81 (78.23)	47.29 (81.53)	21.94 (53.51)			
SEC low vs. ETA				3.09 [1.25; 7.62] 0.014	1.46 [1.05; 2.03] 0.023	0.25 [0.05; 0.44] 0.012
SEC high vs. ETA				3.79 [1.49; 9.60] 0.005	1.52 [1.11; 2.10] 0.010	0.28 [0.09; 0.47] 0.004
PASI100 Response Week 52						
N'	**54**	**55**	**34**			
n (%)	26.38 (47.11)	29.86 (51.48)	9.52 (23.22)			
SEC low vs. ETA				2.92 [1.17; 7.25] 0.021	2.03 [1.07; 3.85] 0.029	0.24 [0.05; 0.43] 0.013

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC high vs. ETA				3.47 [1.40; 8.58] 0.007	2.22 [1.19; 4.15] 0.012	0.28 [0.10; 0.47] 0.003
PASI Rebound Week 52						
N'	54	55	34			
n (%)	0.00 (0.00)	0.00 (0.00)	2.08 (5.07)			
SEC low vs. ETA				0.29 [N.E.; N.E.] N.E.	0.14 [0.01; 2.92] 0.206	-0.05 [-0.12; 0.02] 0.148
SEC high vs. ETA				0.28 [N.E.; N.E.] N.E.	0.14 [0.01; 2.82] 0.199	-0.05 [-0.12; 0.02] 0.148

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.2 PASI Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	13.00 (100.00)	10.94 (91.17)	8.53 (85.30)			
SEC low vs. ETA				2.04 [N.E.; N.E.] N.E.	1.17 [0.88; 1.56] 0.269	0.15 [-0.09; 0.39] 0.227
SEC high vs. ETA				1.67 [0.10; 27.36] 0.721	1.07 [0.76; 1.50] 0.694	0.06 [-0.23; 0.35] 0.692
Age ≥ 12 years, N / N'	**43 / 41**	**46 / 44**	**31 / 25**			
n (%)	42.83 (99.60)	45.89 (99.76)	27.43 (88.48)			
SEC low vs. ETA				6.41 [N.E.; N.E.] N.E.	1.13 [0.98; 1.30] 0.105	0.11 [-0.02; 0.24] 0.085
SEC high vs. ETA				6.99 [N.E.; N.E.] N.E.	1.13 [0.98; 1.30] 0.105	0.11 [-0.02; 0.24] 0.084
PASI75 Response Week 52						
Interaction Test	p=0.208					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	11.00 (84.62)	9.69 (80.75)	8.31 (83.10)			
SEC low vs. ETA				1.07 [0.10; 11.20] 0.958	1.02 [0.70; 1.49] 0.920	0.02 [-0.30; 0.33] 0.925
SEC high vs. ETA				0.84 [0.08; 8.96] 0.883	0.97 [0.64; 1.48] 0.896	-0.02 [-0.37; 0.32] 0.893
Age ≥ 12 years, N / N'	**43 / 41**	**46 / 44**	**31 / 25**			
n (%)	39.37 (91.56)	44.50 (96.74)	21.65 (69.84)			
SEC low vs. ETA				4.61 [1.14; 18.68] 0.032	1.31 [1.00; 1.72] 0.047	0.22 [0.02; 0.41] 0.029
SEC high vs. ETA				13.49 [1.62; 112.06] 0.016	1.39 [1.07; 1.79] 0.013	0.27 [0.09; 0.45] 0.004

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.492**					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	10.00 (76.92)	9.39 (78.25)	7.14 (71.40)			
SEC low vs. ETA				1.31 [0.20; 8.59] 0.779	1.08 [0.65; 1.78] 0.768	0.06 [-0.31; 0.42] 0.768
SEC high vs. ETA				1.43 [0.19; 10.69] 0.727	1.10 [0.65; 1.83] 0.728	0.07 [-0.31; 0.45] 0.724
Age ≥ 12 years, N / N'	**43 / 41**	**46 / 44**	**31 / 25**			
n (%)	33.81 (78.63)	37.90 (82.39)	14.80 (47.74)			
SEC low vs. ETA				3.96 [1.39; 11.26] 0.010	1.65 [1.09; 2.50] 0.019	0.31 [0.09; 0.53] 0.007
SEC high vs. ETA				5.02 [1.73; 14.51] 0.003	1.73 [1.15; 2.59] 0.008	0.35 [0.13; 0.56] 0.002
PASI100 Response Week 52						
Interaction Test	**p=0.169**					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	9.00 (69.23)	5.21 (43.42)	4.07 (40.70)			
SEC low vs. ETA				3.10 [0.57; 16.87] 0.190	1.70 [0.74; 3.95] 0.214	0.29 [-0.11; 0.68] 0.159
SEC high vs. ETA				1.11 [0.20; 6.04] 0.902	1.07 [0.39; 2.92] 0.902	0.03 [-0.39; 0.45] 0.899
Age ≥ 12 years, N / N'	**43 / 41**	**46 / 44**	**31 / 25**			
n (%)	17.38 (40.42)	24.65 (53.59)	5.45 (17.58)			
SEC low vs. ETA				3.15 [1.01; 9.83] 0.049	2.31 [0.96; 5.55] 0.061	0.23 [0.02; 0.43] 0.029
SEC high vs. ETA				5.32 [1.74; 16.26] 0.003	3.06 [1.32; 7.08] 0.009	0.36 [0.16; 0.56] <.001

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.3 PASI Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Male, N / N'	**20 / 20**	**27 / 26**	**16 / 12**			
n (%)	20.00 (100.00)	26.97 (99.89)	13.36 (83.50)			
SEC low vs. ETA				4.35 [N.E.; N.E.] N.E.	1.20 [0.94; 1.53] 0.147	0.17 [-0.04; 0.37] 0.109
SEC high vs. ETA				5.85 [N.E.; N.E.] N.E.	1.20 [0.94; 1.53] 0.152	0.16 [-0.04; 0.37] 0.114
Female, N / N'	**36 / 34**	**31 / 29**	**25 / 22**			
n (%)	35.83 (99.53)	29.86 (96.32)	22.60 (90.40)			
SEC low vs. ETA				4.03 [N.E.; N.E.] N.E.	1.10 [0.95; 1.27] 0.194	0.09 [-0.04; 0.22] 0.173
SEC high vs. ETA				2.69 [0.21; 33.59] 0.443	1.07 [0.91; 1.25] 0.437	0.06 [-0.09; 0.21] 0.429
PASI75 Response Week 52						
Interaction Test	p=0.933					
Male, N / N'	**20 / 20**	**27 / 26**	**16 / 12**			
n (%)	18.00 (90.00)	25.70 (95.19)	12.18 (76.13)			
SEC low vs. ETA				2.67 [0.38; 18.78] 0.324	1.19 [0.84; 1.67] 0.333	0.14 [-0.13; 0.41] 0.311
SEC high vs. ETA				6.09 [0.59; 62.86] 0.130	1.25 [0.91; 1.73] 0.172	0.19 [-0.06; 0.44] 0.133
Female, N / N'	**36 / 34**	**31 / 29**	**25 / 22**			
n (%)	32.37 (89.92)	28.49 (91.90)	17.78 (71.12)			
SEC low vs. ETA				3.57 [0.84; 15.08] 0.084	1.26 [0.95; 1.68] 0.105	0.19 [-0.02; 0.40] 0.081
SEC high vs. ETA				4.61 [0.85; 24.89] 0.076	1.29 [0.97; 1.72] 0.079	0.21 [-0.01; 0.42] 0.057

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.477**					
Male, N / N'	**20 / 20**	**27 / 26**	**16 / 12**			
n (%)	15.00 (75.00)	23.27 (86.19)	10.52 (65.75)			
SEC low vs. ETA				1.54 [0.35; 6.68] 0.568	1.14 [0.73; 1.79] 0.562	0.09 [-0.22; 0.40] 0.558
SEC high vs. ETA				3.16 [0.67; 14.96] 0.147	1.31 [0.88; 1.97] 0.187	0.20 [-0.07; 0.48] 0.150
Female, N / N'	**36 / 34**	**31 / 29**	**25 / 22**			
n (%)	28.81 (80.03)	24.02 (77.48)	11.42 (45.68)			
SEC low vs. ETA				4.65 [1.45; 14.89] 0.010	1.75 [1.09; 2.81] 0.019	0.34 [0.10; 0.59] 0.005
SEC high vs. ETA				4.00 [1.23; 12.98] 0.021	1.70 [1.05; 2.74] 0.031	0.32 [0.07; 0.57] 0.013
PASI100 Response Week 52						
Interaction Test	**p=0.957**					
Male, N / N'	**20 / 20**	**27 / 26**	**16 / 12**			
n (%)	8.00 (40.00)	13.10 (48.52)	3.28 (20.50)			
SEC low vs. ETA				2.54 [0.55; 11.72] 0.232	1.97 [0.63; 6.19] 0.246	0.20 [-0.10; 0.49] 0.199
SEC high vs. ETA				3.58 [0.83; 15.43] 0.087	2.39 [0.81; 7.06] 0.116	0.28 [0.00; 0.56] 0.050
Female, N / N'	**36 / 34**	**31 / 29**	**25 / 22**			
n (%)	18.38 (51.06)	16.76 (54.06)	6.24 (24.96)			
SEC low vs. ETA				3.08 [1.00; 9.54] 0.051	2.05 [0.95; 4.41] 0.067	0.26 [0.02; 0.50] 0.033
SEC high vs. ETA				3.46 [1.08; 11.08] 0.036	2.17 [1.00; 4.69] 0.049	0.29 [0.04; 0.54] 0.022

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.4 PASI Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Baseline PASI ≤ Median, N / N'	**27 / 27**	**29 / 28**	**22 / 19**			
n (%)	27.00 (100.00)	27.92 (96.28)	20.20 (91.82)			
SEC low vs. ETA				2.36 [N.E.; N.E.] N.E.	1.09 [0.94; 1.26] 0.248	0.08 [-0.05; 0.21] 0.225
SEC high vs. ETA				2.12 [0.14; 32.70] 0.590	1.05 [0.89; 1.24] 0.568	0.04 [-0.11; 0.20] 0.563
Baseline PASI > Median, N / N'	**29 / 27**	**29 / 27**	**19 / 15**			
n (%)	28.83 (99.41)	28.91 (99.69)	15.76 (82.95)			
SEC low vs. ETA				6.61 [N.E.; N.E.] N.E.	1.20 [0.96; 1.51] 0.116	0.16 [-0.02; 0.35] 0.085
SEC high vs. ETA				6.75 [N.E.; N.E.] N.E.	1.20 [0.96; 1.51] 0.109	0.17 [-0.02; 0.35] 0.078
PASI75 Response Week 52						
Interaction Test	p=0.782					
Baseline PASI ≤ Median, N / N'	**27 / 27**	**29 / 28**	**22 / 19**			
n (%)	26.00 (96.30)	27.80 (95.86)	17.29 (78.59)			
SEC low vs. ETA				6.73 [0.69; 65.25] 0.100	1.23 [0.96; 1.57] 0.108	0.18 [-0.02; 0.38] 0.081
SEC high vs. ETA				6.27 [0.65; 60.79] 0.113	1.22 [0.95; 1.57] 0.122	0.17 [-0.03; 0.37] 0.094
Baseline PASI > Median, N / N'	**29 / 27**	**29 / 27**	**19 / 15**			
n (%)	24.37 (84.03)	26.39 (91.00)	12.67 (66.68)			

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				2.58 [0.62; 10.76] 0.193	1.26 [0.87; 1.83] 0.223	0.17 [-0.09; 0.44] 0.194
SEC high vs. ETA				4.98 [0.91; 27.21] 0.064	1.37 [0.96; 1.95] 0.087	0.24 [-0.01; 0.49] 0.055
PASI90 Response Week 52						
Interaction Test	**p=0.903**					
Baseline PASI ≤ Median, N / N'	**27 / 27**	**29 / 28**	**22 / 19**			
n (%)	22.00 (81.48)	23.63 (81.48)	11.76 (53.45)			
SEC low vs. ETA				3.72 [1.02; 13.57] 0.047	1.53 [0.98; 2.39] 0.064	0.28 [0.02; 0.54] 0.037
SEC high vs. ETA				3.73 [1.03; 13.57] 0.045	1.53 [0.98; 2.39] 0.064	0.28 [0.02; 0.54] 0.036
Baseline PASI > Median, N / N'	**29 / 27**	**29 / 27**	**19 / 15**			
n (%)	21.81 (75.21)	23.66 (81.59)	10.18 (53.58)			
SEC low vs. ETA				2.58 [0.74; 9.04] 0.138	1.40 [0.87; 2.26] 0.163	0.22 [-0.06; 0.50] 0.130
SEC high vs. ETA				3.75 [0.98; 14.31] 0.053	1.52 [0.96; 2.42] 0.075	0.28 [0.01; 0.55] 0.044
PASI100 Response Week 52						
Interaction Test	**p=0.346**					
Baseline PASI ≤ Median, N / N'	**27 / 27**	**29 / 28**	**22 / 19**			
n (%)	13.00 (48.15)	16.55 (57.07)	3.45 (15.68)			
SEC low vs. ETA				4.89 [1.18; 20.19] 0.028	3.11 [1.03; 9.38] 0.044	0.32 [0.08; 0.57] 0.010
SEC high vs. ETA				6.95 [1.69; 28.52] 0.007	3.68 [1.25; 10.85] 0.018	0.41 [0.17; 0.66] <.001
Baseline PASI > Median, N / N'	**29 / 27**	**29 / 27**	**19 / 15**			
n (%)	13.38 (46.14)	13.31 (45.90)	6.07 (31.95)			

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				1.80 [0.54; 6.04] 0.340	1.44 [0.67; 3.13] 0.351	0.14 [-0.14; 0.42] 0.321
SEC high vs. ETA				1.79 [0.53; 6.00] 0.348	1.44 [0.66; 3.12] 0.359	0.14 [-0.14; 0.42] 0.330

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.5 PASI Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Europe, N / N'	39 / 38	46 / 44	24 / 21			
n (%)	38.83 (99.56)	45.91 (99.80)	21.63 (90.13)			
SEC low vs. ETA				4.42 [N.E.; N.E.] N.E.	1.11 [0.95; 1.29] 0.200	0.09 [-0.04; 0.23] 0.177
SEC high vs. ETA				5.31 [N.E.; N.E.] N.E.	1.11 [0.95; 1.29] 0.189	0.10 [-0.04; 0.23] 0.166
Others, N / N'	17 / 16	12 / 11	17 / 13			
n (%)	17.00 (100.00)	10.92 (91.00)	14.33 (84.29)			
SEC low vs. ETA				3.53 [N.E.; N.E.] N.E.	1.19 [0.95; 1.49] 0.134	0.16 [-0.03; 0.34] 0.100
SEC high vs. ETA				1.84 [0.15; 21.89] 0.631	1.08 [0.81; 1.45] 0.605	0.07 [-0.19; 0.32] 0.602
PASI75 Response Week 52						
Interaction Test	p=0.594					
Europe, N / N'	39 / 38	46 / 44	24 / 21			
n (%)	35.46 (90.92)	44.39 (96.50)	19.89 (82.87)			
SEC low vs. ETA				2.03 [0.40; 10.26] 0.393	1.10 [0.88; 1.37] 0.410	0.08 [-0.11; 0.27] 0.399
SEC high vs. ETA				5.85 [0.64; 53.46] 0.117	1.17 [0.95; 1.44] 0.151	0.14 [-0.04; 0.31] 0.127
Others, N / N'	17 / 16	12 / 11	17 / 13			
n (%)	14.91 (87.71)	9.80 (81.67)	10.07 (59.24)			
SEC low vs. ETA				4.70 [0.79; 27.91] 0.089	1.48 [0.94; 2.36] 0.094	0.28 [-0.01; 0.58] 0.059
SEC high vs. ETA				2.98 [0.48; 18.40] 0.240	1.38 [0.83; 2.30] 0.214	0.22 [-0.11; 0.56] 0.193

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.455**					
Europe, N / N'	**39 / 38**	**46 / 44**	**24 / 21**			
n (%)	30.20 (77.44)	38.66 (84.04)	15.47 (64.46)			
SEC low vs. ETA				1.87 [0.60; 5.87] 0.284	1.20 [0.85; 1.71] 0.306	0.13 [-0.11; 0.37] 0.286
SEC high vs. ETA				2.86 [0.88; 9.32] 0.081	1.30 [0.93; 1.82] 0.118	0.20 [-0.03; 0.42] 0.089
Others, N / N'	**17 / 16**	**12 / 11**	**17 / 13**			
n (%)	13.61 (80.06)	8.63 (71.92)	6.47 (38.06)			
SEC low vs. ETA				6.21 [1.28; 30.09] 0.023	2.11 [1.07; 4.17] 0.032	0.42 [0.11; 0.73] 0.008
SEC high vs. ETA				3.99 [0.78; 20.38] 0.096	1.89 [0.91; 3.94] 0.088	0.34 [-0.02; 0.69] 0.063
PASI100 Response Week 52						
Interaction Test	**p=0.592**					
Europe, N / N'	**39 / 38**	**46 / 44**	**24 / 21**			
n (%)	23.09 (59.21)	28.31 (61.54)	7.28 (30.33)			
SEC low vs. ETA				3.27 [1.10; 9.72] 0.033	1.96 [1.00; 3.84] 0.051	0.29 [0.05; 0.53] 0.020
SEC high vs. ETA				3.61 [1.24; 10.49] 0.018	2.03 [1.05; 3.94] 0.036	0.31 [0.08; 0.55] 0.009
Others, N / N'	**17 / 16**	**12 / 11**	**17 / 13**			
n (%)	3.29 (19.35)	1.55 (12.92)	2.24 (13.18)			
SEC low vs. ETA				1.57 [0.23; 10.58] 0.641	1.48 [0.29; 7.61] 0.638	0.06 [-0.19; 0.32] 0.637
SEC high vs. ETA				0.94 [0.09; 10.35] 0.961	0.94 [0.11; 8.06] 0.956	-0.00 [-0.27; 0.26] 0.985

	Treatment Groups			Comparison		
	SEC low (N=56)	**SEC high (N=58)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.6 PASI Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 24**	**20 / 17**			
n (%)	28.00 (100.00)	24.86 (95.62)	17.37 (86.85)			
SEC low vs. ETA				4.82 [N.E.; N.E.] N.E.	1.15 [0.96; 1.39] 0.132	0.13 [-0.03; 0.29] 0.105
SEC high vs. ETA				3.26 [0.29; 37.04] 0.341	1.10 [0.90; 1.35] 0.355	0.09 [-0.09; 0.27] 0.339
Weight ≥ 50 kg, N / N'	**28 / 26**	**32 / 31**	**21 / 17**			
n (%)	27.83 (99.39)	31.97 (99.91)	18.59 (88.52)			
SEC low vs. ETA				3.70 [N.E.; N.E.] N.E.	1.12 [0.94; 1.35] 0.211	0.11 [-0.05; 0.27] 0.183
SEC high vs. ETA				4.37 [N.E.; N.E.] N.E.	1.13 [0.94; 1.36] 0.191	0.11 [-0.05; 0.27] 0.162
PASI75 Response Week 52						
Interaction Test	N.E.					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 24**	**20 / 17**			
n (%)	25.00 (89.29)	22.49 (86.50)	13.76 (68.80)			
SEC low vs. ETA				3.65 [0.78; 17.04] 0.099	1.30 [0.93; 1.82] 0.127	0.20 [-0.04; 0.45] 0.096
SEC high vs. ETA				2.87 [0.61; 13.55] 0.183	1.26 [0.89; 1.79] 0.200	0.18 [-0.08; 0.43] 0.174
Weight ≥ 50 kg, N / N'	**28 / 26**	**32 / 31**	**21 / 17**			
n (%)	25.37 (90.61)	31.70 (99.06)	16.20 (77.14)			
SEC low vs. ETA				2.80 [0.46; 16.84] 0.262	1.18 [0.88; 1.58] 0.276	0.13 [-0.10; 0.37] 0.255
SEC high vs. ETA				10.49 [N.E.; N.E.] N.E.	1.29 [0.99; 1.68] 0.063	0.22 [0.01; 0.42] 0.036

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.378**					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 24**	**20 / 17**			
n (%)	22.00 (78.57)	19.02 (73.15)	11.43 (57.15)			
SEC low vs. ETA				2.69 [0.75; 9.56] 0.127	1.38 [0.89; 2.13] 0.152	0.21 [-0.06; 0.48] 0.120
SEC high vs. ETA				2.02 [0.57; 7.18] 0.279	1.28 [0.81; 2.03] 0.292	0.16 [-0.12; 0.44] 0.270
Weight ≥ 50 kg, N / N'	**28 / 26**	**32 / 31**	**21 / 17**			
n (%)	21.81 (77.89)	28.27 (88.34)	10.51 (50.05)			
SEC low vs. ETA				3.44 [0.95; 12.42] 0.059	1.56 [0.95; 2.55] 0.077	0.28 [0.00; 0.55] 0.047
SEC high vs. ETA				7.29 [1.78; 29.83] 0.006	1.77 [1.11; 2.81] 0.016	0.38 [0.13; 0.63] 0.003
PASI100 Response Week 52						
Interaction Test	**p=0.016**					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 24**	**20 / 17**			
n (%)	17.00 (60.71)	9.76 (37.54)	6.24 (31.20)			
SEC low vs. ETA				3.32 [0.99; 11.20] 0.053	1.95 [0.94; 4.05] 0.073	0.30 [0.02; 0.57] 0.036
SEC high vs. ETA				1.32 [0.38; 4.62] 0.666	1.20 [0.52; 2.79] 0.666	0.06 [-0.22; 0.35] 0.660
Weight ≥ 50 kg, N / N'	**28 / 26**	**32 / 31**	**21 / 17**			
n (%)	9.38 (33.50)	20.10 (62.81)	3.28 (15.62)			
SEC low vs. ETA				2.69 [0.62; 11.61] 0.185	2.16 [0.67; 7.00] 0.199	0.18 [-0.06; 0.42] 0.149
SEC high vs. ETA				8.80 [2.15; 35.92] 0.002	4.06 [1.39; 11.86] 0.010	0.47 [0.24; 0.71] <.001

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.7 PASI Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
No previous systemic therapy, N / N'	**23 / 21**	**26 / 24**	**22 / 19**			
n (%)	22.83 (99.26)	25.86 (99.46)	20.05 (91.14)			
SEC low vs. ETA				2.27 [N.E.; N.E.] N.E.	1.09 [0.94; 1.27] 0.262	0.08 [-0.06; 0.22] 0.243
SEC high vs. ETA				2.58 [N.E.; N.E.] N.E.	1.09 [0.94; 1.27] 0.249	0.08 [-0.05; 0.22] 0.229
Previous systemic therapy, N / N'	**33 / 33**	**32 / 31**	**19 / 15**			
n (%)	33.00 (100.00)	30.97 (96.78)	15.91 (83.74)			
SEC low vs. ETA				7.24 [N.E.; N.E.] N.E.	1.20 [0.95; 1.51] 0.130	0.16 [-0.03; 0.35] 0.094
SEC high vs. ETA				5.45 [0.47; 62.95] 0.174	1.16 [0.91; 1.47] 0.234	0.13 [-0.07; 0.33] 0.203
PASI75 Response Week 52						
Interaction Test	N.E.					
No previous systemic therapy, N / N'	**23 / 21**	**26 / 24**	**22 / 19**			
n (%)	21.37 (92.91)	25.49 (98.04)	16.81 (76.41)			
SEC low vs. ETA				4.14 [0.50; 34.35] 0.189	1.22 [0.92; 1.61] 0.166	0.17 [-0.06; 0.39] 0.143
SEC high vs. ETA				8.14 [N.E.; N.E.] N.E.	1.28 [0.99; 1.66] 0.057	0.22 [0.02; 0.42] 0.034
Previous systemic therapy, N / N'	**33 / 33**	**32 / 31**	**19 / 15**			
n (%)	29.00 (87.88)	28.70 (89.69)	13.15 (69.21)			

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				3.12 [0.70; 13.77] 0.134	1.27 [0.89; 1.81] 0.182	0.19 [-0.07; 0.44] 0.148
SEC high vs. ETA				3.75 [0.76; 18.46] 0.104	1.30 [0.91; 1.85] 0.148	0.20 [-0.05; 0.46] 0.112
PASI90 Response Week 52						
Interaction Test	**p=0.750**					
No previous systemic therapy, N / N'	**23 / 21**	**26 / 24**	**22 / 19**			
n (%)	18.81 (81.78)	22.02 (84.69)	14.33 (65.14)			
SEC low vs. ETA				2.38 [0.56; 10.14] 0.239	1.26 [0.86; 1.83] 0.237	0.17 [-0.10; 0.43] 0.219
SEC high vs. ETA				2.93 [0.70; 12.32] 0.142	1.30 [0.91; 1.86] 0.149	0.20 [-0.05; 0.45] 0.125
Previous systemic therapy, N / N'	**33 / 33**	**32 / 31**	**19 / 15**			
n (%)	25.00 (75.76)	25.27 (78.97)	7.61 (40.05)			
SEC low vs. ETA				4.53 [1.32; 15.59] 0.017	1.90 [1.03; 3.50] 0.040	0.36 [0.08; 0.63] 0.011
SEC high vs. ETA				5.42 [1.51; 19.45] 0.009	1.98 [1.08; 3.63] 0.028	0.39 [0.12; 0.66] 0.005
PASI100 Response Week 52						
Interaction Test	**p=0.196**					
No previous systemic therapy, N / N'	**23 / 21**	**26 / 24**	**22 / 19**			
n (%)	14.38 (62.52)	13.76 (52.92)	8.17 (37.14)			
SEC low vs. ETA				2.76 [0.82; 9.35] 0.102	1.68 [0.89; 3.20] 0.111	0.25 [-0.03; 0.54] 0.084
SEC high vs. ETA				1.88 [0.58; 6.06] 0.291	1.43 [0.73; 2.78] 0.298	0.16 [-0.13; 0.44] 0.277
Previous systemic therapy, N / N'	**33 / 33**	**32 / 31**	**19 / 15**			
n (%)	12.00 (36.36)	16.10 (50.31)	1.35 (7.11)			

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				7.70 [0.94; 62.76] 0.057	5.45 [0.81; 36.90] 0.082	0.29 [0.09; 0.50] 0.006
SEC high vs. ETA				13.46 [1.66; 109.14] 0.015	7.54 [1.14; 49.95] 0.036	0.43 [0.22; 0.65] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.1 IGA mod 2011 Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
N'	54	55	34			
n (%)	44.18 (78.89)	44.91 (77.43)	23.85 (58.17)			
SEC low vs. ETA				2.66 [1.07; 6.64] 0.036	1.36 [1.00; 1.84] 0.048	0.21 [0.02; 0.40] 0.033
SEC high vs. ETA				2.45 [0.99; 6.03] 0.052	1.33 [0.98; 1.81] 0.066	0.19 [0.00; 0.38] 0.049

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.2 IGA mod 2011 Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.699**					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	11.00 (84.62)	8.56 (71.33)	5.18 (51.80)			
SEC low vs. ETA				4.73 [0.69; 32.32] 0.113	1.64 [0.85; 3.16] 0.142	0.33 [-0.05; 0.70] 0.085
SEC high vs. ETA				2.24 [0.37; 13.58] 0.380	1.38 [0.67; 2.85] 0.387	0.20 [-0.22; 0.61] 0.360
Age ≥ 12 years, N / N'	**43 / 41**	**46 / 44**	**31 / 25**			
n (%)	33.18 (77.16)	36.35 (79.02)	18.67 (60.23)			
SEC low vs. ETA				2.21 [0.78; 6.21] 0.133	1.28 [0.91; 1.80] 0.151	0.17 [-0.05; 0.39] 0.130
SEC high vs. ETA				2.46 [0.88; 6.90] 0.087	1.31 [0.94; 1.83] 0.108	0.19 [-0.03; 0.40] 0.085

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.3 IGA mod 2011 Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.482**					
Male, N / N'	**20 / 20**	**27 / 26**	**16 / 12**			
n (%)	15.00 (75.00)	22.69 (84.04)	10.62 (66.38)			
SEC low vs. ETA				1.49 [0.33; 6.65] 0.602	1.13 [0.72; 1.78] 0.590	0.09 [-0.23; 0.40] 0.588
SEC high vs. ETA				2.59 [0.56; 11.99] 0.223	1.27 [0.84; 1.92] 0.258	0.18 [-0.11; 0.46] 0.226
Female, N / N'	**36 / 34**	**31 / 29**	**25 / 22**			
n (%)	29.18 (81.06)	22.22 (71.68)	13.23 (52.92)			
SEC low vs. ETA				3.73 [1.16; 11.96] 0.027	1.53 [1.02; 2.31] 0.041	0.28 [0.04; 0.52] 0.021
SEC high vs. ETA				2.22 [0.72; 6.86] 0.164	1.35 [0.87; 2.10] 0.177	0.19 [-0.07; 0.45] 0.154

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.4 IGA mod 2011 Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.930**					
Baseline PASI ≤ Median, N / N'	**27 / 27**	**29 / 28**	**22 / 19**			
n (%)	21.00 (77.78)	22.66 (78.14)	13.35 (60.68)			
SEC low vs. ETA				2.23 [0.64; 7.76] 0.209	1.28 [0.86; 1.91] 0.222	0.17 [-0.09; 0.43] 0.199
SEC high vs. ETA				2.28 [0.66; 7.87] 0.192	1.29 [0.87; 1.91] 0.209	0.17 [-0.08; 0.43] 0.185
Baseline PASI > Median, N / N'	**29 / 27**	**29 / 27**	**19 / 15**			
n (%)	23.18 (79.93)	22.25 (76.72)	10.50 (55.26)			
SEC low vs. ETA				3.15 [0.83; 11.96] 0.092	1.45 [0.91; 2.31] 0.119	0.25 [-0.03; 0.53] 0.084
SEC high vs. ETA				2.62 [0.72; 9.57] 0.145	1.39 [0.87; 2.23] 0.172	0.21 [-0.07; 0.50] 0.138

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.5 IGA mod 2011 Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.093**					
Europe, N / N'	**39 / 38**	**46 / 44**	**24 / 21**			
n (%)	29.39 (75.36)	38.25 (83.15)	17.13 (71.37)			
SEC low vs. ETA				1.22 [0.39; 3.87] 0.732	1.06 [0.77; 1.45] 0.735	0.04 [-0.19; 0.27] 0.732
SEC high vs. ETA				1.96 [0.59; 6.52] 0.270	1.17 [0.87; 1.56] 0.303	0.12 [-0.10; 0.33] 0.284
Others, N / N'	**17 / 16**	**12 / 11**	**17 / 13**			
n (%)	14.79 (87.00)	6.66 (55.50)	6.72 (39.53)			
SEC low vs. ETA				9.62 [1.64; 56.31] 0.012	2.21 [1.14; 4.29] 0.018	0.47 [0.18; 0.77] 0.002
SEC high vs. ETA				1.87 [0.40; 8.84] 0.428	1.41 [0.62; 3.22] 0.416	0.16 [-0.22; 0.54] 0.414

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.6 IGA mod 2011 Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.332**					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 24**	**20 / 17**			
n (%)	23.00 (82.14)	18.22 (70.08)	9.44 (47.20)			
SEC low vs. ETA				4.95 [1.33; 18.38] 0.017	1.74 [1.04; 2.91] 0.033	0.35 [0.08; 0.62] 0.010
SEC high vs. ETA				2.57 [0.74; 8.98] 0.139	1.49 [0.86; 2.58] 0.157	0.23 [-0.06; 0.52] 0.124
Weight ≥ 50 kg, N / N'	**28 / 26**	**32 / 31**	**21 / 17**			
n (%)	21.18 (75.64)	26.69 (83.41)	14.41 (68.62)			
SEC low vs. ETA				1.41 [0.39; 5.16] 0.603	1.10 [0.76; 1.60] 0.605	0.07 [-0.19; 0.33] 0.600
SEC high vs. ETA				2.26 [0.60; 8.59] 0.231	1.22 [0.87; 1.71] 0.257	0.15 [-0.10; 0.39] 0.233

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.7 IGA mod 2011 Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.615**					
No previous systemic therapy, N / N'	**23 / 21**	**26 / 24**	**22 / 19**			
n (%)	20.18 (87.74)	20.22 (77.77)	14.50 (65.91)			
SEC low vs. ETA				3.67 [0.72; 18.88] 0.119	1.33 [0.93; 1.90] 0.113	0.22 [-0.03; 0.47] 0.089
SEC high vs. ETA				1.79 [0.48; 6.77] 0.388	1.18 [0.81; 1.73] 0.394	0.12 [-0.15; 0.38] 0.381
Previous systemic therapy, N / N'	**33 / 33**	**32 / 31**	**19 / 15**			
n (%)	24.00 (72.73)	24.69 (77.16)	9.35 (49.21)			
SEC low vs. ETA				2.70 [0.82; 8.88] 0.103	1.48 [0.88; 2.48] 0.137	0.24 [-0.04; 0.51] 0.097
SEC high vs. ETA				3.40 [0.98; 11.77] 0.054	1.57 [0.94; 2.62] 0.084	0.28 [0.00; 0.56] 0.047

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

8.0 CDLQI, Return Rates (FAS)

	Treatment Groups			
	SEC low (N=56)	**SEC high (N=58)**	**ETA (N=41)**	**Total (N=155)**
Number of patients with valid data n (%)				
Baseline Returns	56 (100.0)	58 (100.0)	41 (100.0)	155 (100.0)
Week 4 Returns	51 (91.1)	54 (93.1)	40 (97.6)	145 (93.5)
Week 8 Returns	53 (94.6)	54 (93.1)	40 (97.6)	147 (94.8)
Week 12 Returns	44 (78.6)	52 (89.7)	34 (82.9)	130 (83.9)
Week 24 Returns	54 (96.4)	54 (93.1)	39 (95.1)	147 (94.8)
Week 36 Returns	54 (96.4)	52 (89.7)	33 (80.5)	139 (89.7)
Week 52 Returns	52 (92.9)	54 (93.1)	35 (85.4)	141 (91.0)
Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.				

8.1 CDLQI, Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
N'	55	56	41		
Baseline Mean (SD)	12.38 (7.18)	10.90 (7.07)	10.34 (7.67)		
Week 4 Adjusted Mean Change (SE)	-4.88 (0.67)	-4.81 (0.66)	-5.34 (0.76)		
Week 8 Adjusted Mean Change (SE)	-5.43 (0.66)	-6.94 (0.66)	-6.11 (0.76)		
Week 12 Adjusted Mean Change (SE)	-6.67 (0.70)	-6.77 (0.66)	-7.73 (0.81)		
Week 24 Adjusted Mean Change (SE)	-9.07 (0.66)	-8.51 (0.66)	-7.03 (0.77)		
Week 36 Adjusted Mean Change (SE)	-9.11 (0.66)	-8.12 (0.66)	-7.20 (0.81)		
Week 52 Adjusted Mean Change (SE)	-9.50 (0.67)	-9.09 (0.66)	-8.23 (0.80)	-1.26 [-3.31; 0.78] 0.225	-0.86 [-2.89; 1.17] 0.405

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.2 CDLQI, Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.105					
Age < 12 years, N	13	12	10		
N'	13	11	10		
Baseline Mean (SD)	12.08 (7.86)	12.42 (7.53)	13.80 (3.74)		
Week 4 Adjusted Mean Change (SE)	-3.31 (1.40)	-2.41 (1.49)	-2.68 (1.52)		
Week 8 Adjusted Mean Change (SE)	-3.39 (1.33)	-8.39 (1.49)	-0.86 (1.57)		
Week 12 Adjusted Mean Change (SE)	-5.32 (1.63)	-8.08 (1.54)	-3.62 (1.70)		
Week 24 Adjusted Mean Change (SE)	-9.78 (1.33)	-10.02 (1.49)	-5.58 (1.52)		
Week 36 Adjusted Mean Change (SE)	-10.24 (1.33)	-9.14 (1.44)	-5.46 (1.57)		
Week 52 Adjusted Mean Change (SE)	-9.78 (1.33)	-8.87 (1.44)	-8.46 (1.57)	-1.31 [-5.34; 2.72] 0.523	-0.41 [-4.58; 3.77] 0.849
Age ≥ 12 years, N	43	46	31		
N'	42	45	31		
Baseline Mean (SD)	12.47 (7.06)	10.50 (6.98)	9.23 (8.30)		
Week 4 Adjusted Mean Change (SE)	-5.29 (0.75)	-5.35 (0.72)	-6.22 (0.87)		
Week 8 Adjusted Mean Change (SE)	-6.07 (0.75)	-6.61 (0.72)	-7.70 (0.86)		
Week 12 Adjusted Mean Change (SE)	-6.93 (0.77)	-6.49 (0.72)	-8.92 (0.90)		
Week 24 Adjusted Mean Change (SE)	-8.83 (0.75)	-8.17 (0.72)	-7.50 (0.88)		
Week 36 Adjusted Mean Change (SE)	-8.73 (0.75)	-7.85 (0.74)	-7.77 (0.94)		

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.38 (0.76)	-9.16 (0.72)	-8.13 (0.91)	-1.25 [-3.59; 1.08] 0.293	-1.04 [-3.32; 1.25] 0.374

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.3 CDLQI, Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.003					
Male, N	**20**	**27**	**16**		
N'	20	27	16		
Baseline Mean (SD)	13.10 (7.64)	11.22 (6.02)	8.81 (7.79)		
Week 4 Adjusted Mean Change (SE)	-2.74 (1.08)	-5.60 (0.94)	-5.95 (1.19)		
Week 8 Adjusted Mean Change (SE)	-2.67 (1.07)	-8.08 (0.94)	-7.42 (1.22)		
Week 12 Adjusted Mean Change (SE)	-4.51 (1.17)	-8.22 (0.94)	-9.19 (1.28)		
Week 24 Adjusted Mean Change (SE)	-8.62 (1.07)	-10.03 (0.92)	-6.67 (1.25)		
Week 36 Adjusted Mean Change (SE)	-8.72 (1.07)	-10.18 (0.95)	-7.51 (1.31)		
Week 52 Adjusted Mean Change (SE)	-9.00 (1.08)	-10.05 (0.94)	-8.07 (1.28)	-0.93 [-4.23; 2.37] 0.580	-1.98 [-5.09; 1.13] 0.212
Female, N	**36**	**31**	**25**		
N'	35	29	25		
Baseline Mean (SD)	11.97 (6.99)	10.61 (7.96)	11.32 (7.58)		
Week 4 Adjusted Mean Change (SE)	-6.11 (0.83)	-4.06 (0.88)	-4.94 (0.96)		
Week 8 Adjusted Mean Change (SE)	-7.06 (0.82)	-5.89 (0.88)	-5.31 (0.95)		
Week 12 Adjusted Mean Change (SE)	-7.83 (0.86)	-5.42 (0.90)	-6.83 (1.01)		
Week 24 Adjusted Mean Change (SE)	-9.31 (0.81)	-7.05 (0.90)	-7.19 (0.95)		
Week 36 Adjusted Mean Change (SE)	-9.31 (0.81)	-6.29 (0.89)	-6.99 (1.01)		

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.77 (0.82)	-8.20 (0.88)	-8.30 (0.99)	-1.47 [-4.00; 1.06] 0.254	0.10 [-2.51; 2.71] 0.939

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.4 CDLQI, Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.565					
Baseline PASI ≤ Median, N	**27**	**29**	**22**		
N'	27	28	22		
Baseline Mean (SD)	11.07 (6.62)	9.62 (5.55)	9.59 (7.33)		
Week 4 Adjusted Mean Change (SE)	-4.56 (0.96)	-5.23 (0.92)	-6.16 (1.04)		
Week 8 Adjusted Mean Change (SE)	-5.51 (0.95)	-6.32 (0.93)	-6.09 (1.05)		
Week 12 Adjusted Mean Change (SE)	-7.02 (0.96)	-5.55 (0.94)	-7.59 (1.06)		
Week 24 Adjusted Mean Change (SE)	-8.66 (0.94)	-7.97 (0.94)	-7.20 (1.05)		
Week 36 Adjusted Mean Change (SE)	-9.29 (0.94)	-6.97 (0.93)	-7.03 (1.07)		
Week 52 Adjusted Mean Change (SE)	-9.62 (0.95)	-8.32 (0.93)	-7.83 (1.09)	-1.80 [-4.63; 1.04] 0.214	-0.49 [-3.30; 2.31] 0.730
Baseline PASI > Median, N	**29**	**29**	**19**		
N'	28	28	19		
Baseline Mean (SD)	13.59 (7.58)	12.17 (8.22)	11.21 (8.16)		
Week 4 Adjusted Mean Change (SE)	-5.19 (0.95)	-4.31 (0.94)	-4.32 (1.14)		
Week 8 Adjusted Mean Change (SE)	-5.37 (0.94)	-7.57 (0.93)	-6.11 (1.12)		
Week 12 Adjusted Mean Change (SE)	-6.20 (1.05)	-7.99 (0.94)	-7.96 (1.27)		
Week 24 Adjusted Mean Change (SE)	-9.49 (0.94)	-9.04 (0.92)	-6.82 (1.14)		
Week 36 Adjusted Mean Change (SE)	-8.94 (0.94)	-9.32 (0.95)	-7.49 (1.27)		

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.39 (0.95)	-9.87 (0.93)	-8.72 (1.18)	-0.67 [-3.64; 2.30] 0.658	-1.15 [-4.11; 1.80] 0.443

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.5 CDLQI, Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.805					
Europe, N	**39**	**46**	**24**		
N'	39	45	24		
Baseline Mean (SD)	12.64 (7.06)	10.22 (6.59)	9.38 (8.00)		
Week 4 Adjusted Mean Change (SE)	-5.04 (0.80)	-5.28 (0.73)	-5.35 (0.99)		
Week 8 Adjusted Mean Change (SE)	-5.96 (0.79)	-7.12 (0.73)	-7.19 (1.00)		
Week 12 Adjusted Mean Change (SE)	-7.20 (0.81)	-6.63 (0.73)	-8.14 (1.03)		
Week 24 Adjusted Mean Change (SE)	-9.08 (0.78)	-8.49 (0.73)	-8.12 (1.00)		
Week 36 Adjusted Mean Change (SE)	-9.63 (0.78)	-8.38 (0.74)	-8.41 (1.03)		
Week 52 Adjusted Mean Change (SE)	-9.79 (0.78)	-9.25 (0.73)	-8.95 (1.03)	-0.84 [-3.39; 1.71] 0.519	-0.29 [-2.78; 2.19] 0.816
Others, N	**17**	**12**	**17**		
N'	16	11	17		
Baseline Mean (SD)	11.76 (7.64)	13.50 (8.47)	11.71 (7.17)		
Week 4 Adjusted Mean Change (SE)	-4.43 (1.23)	-2.81 (1.51)	-5.41 (1.20)		
Week 8 Adjusted Mean Change (SE)	-4.14 (1.21)	-6.22 (1.46)	-4.63 (1.17)		
Week 12 Adjusted Mean Change (SE)	-5.05 (1.42)	-7.60 (1.56)	-7.21 (1.28)		
Week 24 Adjusted Mean Change (SE)	-9.07 (1.23)	-8.67 (1.51)	-5.48 (1.20)		
Week 36 Adjusted Mean Change (SE)	-7.83 (1.21)	-7.07 (1.51)	-5.25 (1.32)		

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-8.77 (1.26)	-8.50 (1.46)	-7.21 (1.25)	-1.56 [-5.05; 1.93] 0.380	-1.28 [-5.06; 2.49] 0.505

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.6 CDLQI, Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.130					
Weight < 50 kg, N	**28**	**26**	**20**		
N'	28	24	20		
Baseline Mean (SD)	12.86 (7.16)	12.12 (7.52)	11.15 (5.30)		
Week 4 Adjusted Mean Change (SE)	-4.66 (0.93)	-3.62 (1.00)	-3.81 (1.08)		
Week 8 Adjusted Mean Change (SE)	-4.90 (0.92)	-7.16 (1.00)	-4.03 (1.09)		
Week 12 Adjusted Mean Change (SE)	-6.50 (1.04)	-6.94 (1.03)	-6.31 (1.18)		
Week 24 Adjusted Mean Change (SE)	-9.64 (0.92)	-8.93 (1.01)	-5.61 (1.10)		
Week 36 Adjusted Mean Change (SE)	-9.18 (0.91)	-7.90 (1.00)	-5.28 (1.16)		
Week 52 Adjusted Mean Change (SE)	-9.77 (0.92)	-9.13 (0.98)	-8.01 (1.14)	-1.76 [-4.64; 1.11] 0.230	-1.12 [-4.07; 1.83] 0.457
Weight ≥ 50 kg, N	**28**	**32**	**21**		
N'	27	32	21		
Baseline Mean (SD)	11.89 (7.30)	9.91 (6.63)	9.57 (9.46)		
Week 4 Adjusted Mean Change (SE)	-5.09 (0.95)	-5.71 (0.86)	-6.83 (1.07)		
Week 8 Adjusted Mean Change (SE)	-5.96 (0.94)	-6.79 (0.86)	-8.05 (1.05)		
Week 12 Adjusted Mean Change (SE)	-6.78 (0.95)	-6.68 (0.86)	-9.05 (1.09)		
Week 24 Adjusted Mean Change (SE)	-8.49 (0.93)	-8.24 (0.85)	-8.38 (1.07)		
Week 36 Adjusted Mean Change (SE)	-9.02 (0.94)	-8.29 (0.88)	-9.03 (1.13)		

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.19 (0.95)	-9.07 (0.87)	-8.47 (1.11)	-0.72 [-3.59; 2.15] 0.621	-0.60 [-3.36; 2.16] 0.671

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.7 CDLQI, Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.885					
No previous systemic therapy, N	**23**	**26**	**22**		
N'	22	24	22		
Baseline Mean (SD)	10.65 (7.96)	9.50 (7.13)	9.68 (7.14)		
Week 4 Adjusted Mean Change (SE)	-5.49 (1.09)	-5.70 (0.99)	-5.94 (1.05)		
Week 8 Adjusted Mean Change (SE)	-5.75 (1.05)	-7.57 (0.99)	-6.40 (1.05)		
Week 12 Adjusted Mean Change (SE)	-7.11 (1.12)	-7.70 (0.99)	-7.64 (1.15)		
Week 24 Adjusted Mean Change (SE)	-8.89 (1.04)	-9.15 (0.99)	-7.49 (1.07)		
Week 36 Adjusted Mean Change (SE)	-10.12 (1.05)	-9.24 (0.99)	-8.87 (1.11)		
Week 52 Adjusted Mean Change (SE)	-9.74 (1.05)	-9.20 (0.99)	-8.98 (1.07)	-0.76 [-3.70; 2.19] 0.614	-0.21 [-3.07; 2.65] 0.884
Previous systemic therapy, N	**33**	**32**	**19**		
N'	33	32	19		
Baseline Mean (SD)	13.58 (6.43)	12.03 (6.92)	11.11 (8.37)		
Week 4 Adjusted Mean Change (SE)	-4.48 (0.86)	-4.14 (0.88)	-4.67 (1.11)		
Week 8 Adjusted Mean Change (SE)	-5.19 (0.86)	-6.48 (0.88)	-5.77 (1.11)		
Week 12 Adjusted Mean Change (SE)	-6.36 (0.91)	-6.04 (0.90)	-7.71 (1.13)		
Week 24 Adjusted Mean Change (SE)	-9.19 (0.86)	-8.03 (0.88)	-6.51 (1.11)		
Week 36 Adjusted Mean Change (SE)	-8.44 (0.85)	-7.22 (0.90)	-5.22 (1.20)		

	Treatment Groups			Comparisons	
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.33 (0.87)	-9.05 (0.88)	-7.32 (1.20)	-2.01 [-4.92; 0.90] 0.176	-1.73 [-4.65; 1.19] 0.245

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

9.0 CDLQI (Age ≤ 16), Return Rates (FAS)

	Treatment Groups			
	SEC low (N=47)	**SEC high (N=47)**	**ETA (N=34)**	**Total (N=128)**
Number of patients with valid data n (%)				
Baseline Returns	47 (100.0)	47 (100.0)	34 (100.0)	128 (100.0)
Week 4 Returns	44 (93.6)	43 (91.5)	33 (97.1)	120 (93.8)
Week 8 Returns	44 (93.6)	43 (91.5)	33 (97.1)	120 (93.8)
Week 12 Returns	35 (74.5)	41 (87.2)	28 (82.4)	104 (81.3)
Week 24 Returns	41 (87.2)	39 (83.0)	28 (82.4)	108 (84.4)
Week 36 Returns	35 (74.5)	34 (72.3)	23 (67.6)	92 (71.9)
Week 52 Returns	34 (72.3)	36 (76.6)	24 (70.6)	94 (73.4)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.1 CDLQI (Age ≤ 16), Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
N'	46	45	34		
Baseline Mean (SD)	11.68 (7.36)	11.11 (7.47)	9.76 (6.49)		
Week 4 Adjusted Mean Change (SE)	-5.08 (0.71)	-4.46 (0.72)	-4.63 (0.82)		
Week 8 Adjusted Mean Change (SE)	-5.36 (0.71)	-7.26 (0.72)	-5.11 (0.82)		
Week 12 Adjusted Mean Change (SE)	-6.95 (0.76)	-6.95 (0.73)	-6.91 (0.87)		
Week 24 Adjusted Mean Change (SE)	-9.00 (0.73)	-8.36 (0.74)	-6.30 (0.87)		
Week 36 Adjusted Mean Change (SE)	-8.68 (0.77)	-7.86 (0.78)	-6.47 (0.93)		
Week 52 Adjusted Mean Change (SE)	-9.22 (0.77)	-8.66 (0.76)	-8.21 (0.92)	-1.01 [-3.37; 1.34] 0.398	-0.45 [-2.79; 1.89] 0.707

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.2 CDLQI (Age ≤ 16), Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.208					
Age < 12 years, N	**13**	**12**	**10**		
N'	13	11	10		
Baseline Mean (SD)	12.08 (7.86)	12.42 (7.53)	13.80 (3.74)		
Week 4 Adjusted Mean Change (SE)	-3.02 (1.36)	-2.12 (1.45)	-2.40 (1.48)		
Week 8 Adjusted Mean Change (SE)	-3.10 (1.29)	-8.11 (1.45)	-0.58 (1.53)		
Week 12 Adjusted Mean Change (SE)	-5.02 (1.59)	-7.79 (1.50)	-3.34 (1.66)		
Week 24 Adjusted Mean Change (SE)	-9.48 (1.29)	-9.73 (1.45)	-5.30 (1.48)		
Week 36 Adjusted Mean Change (SE)	-9.94 (1.29)	-8.85 (1.41)	-5.18 (1.53)		
Week 52 Adjusted Mean Change (SE)	-9.48 (1.29)	-8.58 (1.41)	-8.18 (1.53)	-1.30 [-5.22; 2.62] 0.515	-0.40 [-4.47; 3.66] 0.846
Age ≥ 12 years, N	**34**	**35**	**24**		
N'	33	34	24		
Baseline Mean (SD)	11.53 (7.27)	10.66 (7.51)	8.08 (6.70)		
Week 4 Adjusted Mean Change (SE)	-5.77 (0.81)	-5.15 (0.81)	-5.61 (0.97)		
Week 8 Adjusted Mean Change (SE)	-6.28 (0.83)	-6.99 (0.81)	-6.88 (0.96)		
Week 12 Adjusted Mean Change (SE)	-7.47 (0.85)	-6.68 (0.81)	-8.25 (1.00)		
Week 24 Adjusted Mean Change (SE)	-8.69 (0.86)	-7.87 (0.84)	-6.58 (1.05)		
Week 36 Adjusted Mean Change (SE)	-7.72 (0.93)	-7.38 (0.91)	-6.89 (1.15)		

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-8.83 (0.94)	-8.70 (0.88)	-7.87 (1.12)	-0.96 [-3.85; 1.92] 0.512	-0.84 [-3.64; 1.97] 0.559

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.3 CDLQI (Age ≤ 16), Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.094					
Male, N	**14**	**22**	**13**		
N'	14	22	13		
Baseline Mean (SD)	11.29 (8.00)	11.50 (6.46)	7.38 (5.99)		
Week 4 Adjusted Mean Change (SE)	-3.55 (1.26)	-4.74 (1.03)	-4.43 (1.31)		
Week 8 Adjusted Mean Change (SE)	-2.77 (1.26)	-7.96 (1.03)	-6.23 (1.35)		
Week 12 Adjusted Mean Change (SE)	-6.15 (1.46)	-7.98 (1.03)	-8.07 (1.43)		
Week 24 Adjusted Mean Change (SE)	-9.47 (1.32)	-9.99 (1.03)	-4.82 (1.49)		
Week 36 Adjusted Mean Change (SE)	-8.56 (1.46)	-10.46 (1.17)	-6.25 (1.73)		
Week 52 Adjusted Mean Change (SE)	-9.45 (1.46)	-9.67 (1.14)	-8.12 (1.63)	-1.33 [-5.64; 2.97] 0.543	-1.55 [-5.47; 2.37] 0.437
Female, N	**33**	**25**	**21**		
N'	32	23	21		
Baseline Mean (SD)	11.85 (7.19)	10.76 (8.38)	11.24 (6.48)		
Week 4 Adjusted Mean Change (SE)	-5.78 (0.85)	-4.13 (0.98)	-4.75 (1.04)		
Week 8 Adjusted Mean Change (SE)	-6.56 (0.85)	-6.56 (0.98)	-4.47 (1.03)		
Week 12 Adjusted Mean Change (SE)	-7.31 (0.89)	-5.94 (1.01)	-6.26 (1.08)		
Week 24 Adjusted Mean Change (SE)	-8.85 (0.86)	-6.70 (1.04)	-6.94 (1.06)		
Week 36 Adjusted Mean Change (SE)	-8.82 (0.89)	-5.84 (1.03)	-6.46 (1.10)		

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.23 (0.90)	-7.75 (1.01)	-8.17 (1.10)	-1.06 [-3.86; 1.74] 0.456	0.43 [-2.51; 3.36] 0.776

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.4 CDLQI (Age ≤ 16), Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.712					
Baseline PASI ≤ Median, N	21	24	17		
N'	21	23	17		
Baseline Mean (SD)	9.52 (6.46)	9.46 (5.59)	9.71 (5.79)		
Week 4 Adjusted Mean Change (SE)	-4.67 (1.05)	-5.02 (0.99)	-5.01 (1.15)		
Week 8 Adjusted Mean Change (SE)	-5.23 (1.05)	-6.22 (1.00)	-4.83 (1.17)		
Week 12 Adjusted Mean Change (SE)	-7.34 (1.07)	-5.42 (1.02)	-6.62 (1.17)		
Week 24 Adjusted Mean Change (SE)	-7.73 (1.09)	-7.60 (1.04)	-5.91 (1.26)		
Week 36 Adjusted Mean Change (SE)	-8.35 (1.16)	-6.70 (1.02)	-5.97 (1.30)		
Week 52 Adjusted Mean Change (SE)	-8.42 (1.16)	-7.91 (1.02)	-8.08 (1.34)	-0.34 [-3.82; 3.13] 0.847	0.17 [-3.13; 3.47] 0.919
Baseline PASI > Median, N	26	23	17		
N'	25	22	17		
Baseline Mean (SD)	13.42 (7.69)	12.83 (8.84)	9.82 (7.31)		
Week 4 Adjusted Mean Change (SE)	-5.44 (0.97)	-3.74 (1.05)	-4.17 (1.17)		
Week 8 Adjusted Mean Change (SE)	-5.49 (0.97)	-8.36 (1.03)	-5.34 (1.15)		
Week 12 Adjusted Mean Change (SE)	-6.40 (1.11)	-8.54 (1.05)	-7.19 (1.29)		
Week 24 Adjusted Mean Change (SE)	-10.01 (0.98)	-9.16 (1.07)	-6.62 (1.20)		
Week 36 Adjusted Mean Change (SE)	-8.95 (1.03)	-9.44 (1.22)	-6.96 (1.33)		

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.87 (1.04)	-9.54 (1.16)	-8.29 (1.26)	-1.58 [-4.81; 1.64] 0.335	-1.25 [-4.62; 2.12] 0.466

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.5 CDLQI (Age ≤ 16), Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.435					
Europe, N	**31**	**35**	**18**		
N'	31	34	18		
Baseline Mean (SD)	11.74 (7.23)	10.29 (7.04)	8.94 (6.96)		
Week 4 Adjusted Mean Change (SE)	-5.74 (0.85)	-5.05 (0.81)	-4.87 (1.10)		
Week 8 Adjusted Mean Change (SE)	-6.27 (0.86)	-7.69 (0.82)	-6.45 (1.12)		
Week 12 Adjusted Mean Change (SE)	-7.88 (0.89)	-6.87 (0.82)	-7.47 (1.14)		
Week 24 Adjusted Mean Change (SE)	-9.03 (0.88)	-8.20 (0.83)	-8.18 (1.20)		
Week 36 Adjusted Mean Change (SE)	-10.10 (0.93)	-7.90 (0.89)	-8.45 (1.23)		
Week 52 Adjusted Mean Change (SE)	-10.32 (0.93)	-8.84 (0.88)	-9.57 (1.27)	-0.75 [-3.84; 2.35] 0.636	0.73 [-2.29; 3.76] 0.634
Others, N	**16**	**12**	**16**		
N'	15	11	16		
Baseline Mean (SD)	11.56 (7.84)	13.50 (8.47)	10.69 (6.01)		
Week 4 Adjusted Mean Change (SE)	-3.70 (1.23)	-2.51 (1.46)	-4.45 (1.19)		
Week 8 Adjusted Mean Change (SE)	-3.50 (1.20)	-5.95 (1.41)	-3.64 (1.17)		
Week 12 Adjusted Mean Change (SE)	-4.84 (1.44)	-7.31 (1.51)	-6.35 (1.29)		
Week 24 Adjusted Mean Change (SE)	-8.88 (1.23)	-8.95 (1.51)	-4.38 (1.22)		
Week 36 Adjusted Mean Change (SE)	-5.85 (1.30)	-7.73 (1.51)	-4.09 (1.37)		

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-6.95 (1.34)	-8.09 (1.46)	-6.78 (1.29)	-0.16 [-3.81; 3.48] 0.930	-1.31 [-5.13; 2.52] 0.502

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.6 CDLQI (Age ≤ 16), Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.312					
Weight < 50 kg, N	**28**	**26**	**20**		
N'	28	24	20		
Baseline Mean (SD)	12.86 (7.16)	12.12 (7.52)	11.15 (5.30)		
Week 4 Adjusted Mean Change (SE)	-4.36 (0.91)	-3.31 (0.98)	-3.51 (1.05)		
Week 8 Adjusted Mean Change (SE)	-4.62 (0.90)	-6.86 (0.97)	-3.73 (1.07)		
Week 12 Adjusted Mean Change (SE)	-6.24 (1.02)	-6.63 (1.01)	-6.00 (1.16)		
Week 24 Adjusted Mean Change (SE)	-9.34 (0.90)	-8.87 (1.01)	-5.31 (1.07)		
Week 36 Adjusted Mean Change (SE)	-8.56 (0.93)	-8.01 (0.99)	-4.98 (1.13)		
Week 52 Adjusted Mean Change (SE)	-9.25 (0.94)	-8.79 (0.98)	-7.71 (1.11)	-1.54 [-4.40; 1.31] 0.288	-1.08 [-3.98; 1.82] 0.465
Weight ≥ 50 kg, N	**19**	**21**	**14**		
N'	18	21	14		
Baseline Mean (SD)	9.95 (7.49)	9.86 (7.40)	7.79 (7.66)		
Week 4 Adjusted Mean Change (SE)	-6.10 (1.11)	-5.76 (1.04)	-6.30 (1.29)		
Week 8 Adjusted Mean Change (SE)	-6.50 (1.13)	-7.70 (1.04)	-7.07 (1.26)		
Week 12 Adjusted Mean Change (SE)	-7.83 (1.15)	-7.28 (1.04)	-8.22 (1.29)		
Week 24 Adjusted Mean Change (SE)	-8.13 (1.21)	-7.72 (1.08)	-7.88 (1.48)		
Week 36 Adjusted Mean Change (SE)	-8.59 (1.37)	-7.41 (1.25)	-9.23 (1.62)		

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-8.79 (1.37)	-8.24 (1.21)	-8.61 (1.62)	-0.18 [-4.34; 3.98] 0.931	0.37 [-3.60; 4.35] 0.854

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.7 CDLQI (Age ≤ 16), Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.744					
No previous systemic therapy, N	**19**	**20**	**19**		
N'	18	18	19		
Baseline Mean (SD)	10.11 (8.58)	9.60 (7.57)	8.63 (5.62)		
Week 4 Adjusted Mean Change (SE)	-5.36 (1.14)	-5.29 (1.12)	-4.78 (1.11)		
Week 8 Adjusted Mean Change (SE)	-5.18 (1.14)	-7.51 (1.12)	-5.33 (1.11)		
Week 12 Adjusted Mean Change (SE)	-6.86 (1.24)	-7.29 (1.12)	-6.84 (1.21)		
Week 24 Adjusted Mean Change (SE)	-8.57 (1.14)	-9.11 (1.14)	-7.35 (1.16)		
Week 36 Adjusted Mean Change (SE)	-9.95 (1.16)	-9.16 (1.19)	-8.54 (1.21)		
Week 52 Adjusted Mean Change (SE)	-9.70 (1.16)	-9.36 (1.19)	-8.89 (1.16)	-0.81 [-4.03; 2.41] 0.622	-0.47 [-3.72; 2.79] 0.779
Previous systemic therapy, N	**28**	**27**	**15**		
N'	28	27	15		
Baseline Mean (SD)	12.75 (6.35)	12.22 (7.34)	11.20 (7.40)		
Week 4 Adjusted Mean Change (SE)	-4.89 (0.91)	-3.88 (0.94)	-4.42 (1.23)		
Week 8 Adjusted Mean Change (SE)	-5.44 (0.91)	-7.10 (0.94)	-4.82 (1.23)		
Week 12 Adjusted Mean Change (SE)	-7.00 (0.97)	-6.73 (0.96)	-6.88 (1.25)		
Week 24 Adjusted Mean Change (SE)	-9.31 (0.95)	-7.82 (0.98)	-4.95 (1.32)		
Week 36 Adjusted Mean Change (SE)	-7.59 (1.03)	-6.88 (1.03)	-3.36 (1.46)		

	Treatment Groups			Comparisons	
	SEC low (N=47)	SEC high (N=47)	ETA (N=34)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-8.79 (1.05)	-8.17 (0.99)	-7.12 (1.53)	-1.66 [-5.30; 1.97] 0.369	-1.05 [-4.62; 2.53] 0.566

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 4 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients $\leq$ 16 years at time of assessment were considered. The table is based on all patients who were $\leq$ 16 years at Baseline.

10.1 CDLQI Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
N'	52	54	35			
n (%)	31.28 (55.86)	39.58 (68.24)	21.84 (53.27)			
SEC low vs. ETA				1.11 [0.49; 2.53] 0.806	1.05 [0.72; 1.53] 0.805	0.03 [-0.18; 0.23] 0.805
SEC high vs. ETA				1.87 [0.80; 4.40] 0.149	1.28 [0.90; 1.82] 0.163	0.15 [-0.05; 0.35] 0.145

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.2 CDLQI Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	p=0.645					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	8.00 (61.54)	7.48 (62.33)	4.21 (42.10)			
SEC low vs. ETA				2.13 [0.40; 11.34] 0.377	1.47 [0.62; 3.50] 0.386	0.19 [-0.22; 0.61] 0.355
SEC high vs. ETA				2.20 [0.38; 12.61] 0.376	1.48 [0.61; 3.60] 0.383	0.20 [-0.22; 0.63] 0.353
Age ≥ 12 years, N / N'	**43 / 39**	**46 / 43**	**31 / 26**			
n (%)	23.28 (54.14)	32.10 (69.78)	17.63 (56.87)			
SEC low vs. ETA				0.90 [0.35; 2.32] 0.822	0.95 [0.62; 1.46] 0.821	-0.03 [-0.26; 0.21] 0.820
SEC high vs. ETA				1.74 [0.66; 4.62] 0.266	1.23 [0.84; 1.78] 0.282	0.13 [-0.10; 0.36] 0.264

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.3 CDLQI Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.060**					
Male, N / N'	**20 / 19**	**27 / 25**	**16 / 13**			
n (%)	9.20 (46.00)	22.64 (83.85)	9.36 (58.50)			
SEC low vs. ETA				0.61 [0.16; 2.34] 0.473	0.79 [0.41; 1.50] 0.466	-0.13 [-0.46; 0.21] 0.462
SEC high vs. ETA				3.58 [0.81; 15.81] 0.092	1.44 [0.90; 2.29] 0.129	0.25 [-0.04; 0.55] 0.089
Female, N / N'	**36 / 33**	**31 / 29**	**25 / 22**			
n (%)	22.08 (61.33)	16.94 (54.65)	12.48 (49.92)			
SEC low vs. ETA				1.58 [0.55; 4.53] 0.395	1.23 [0.76; 2.00] 0.404	0.11 [-0.15; 0.37] 0.389
SEC high vs. ETA				1.21 [0.41; 3.56] 0.735	1.09 [0.65; 1.85] 0.735	0.05 [-0.22; 0.32] 0.733

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.4 CDLQI Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.835**					
Baseline PASI ≤ Median, N / N'	**27 / 26**	**29 / 27**	**22 / 19**			
n (%)	13.20 (48.89)	18.34 (63.24)	11.58 (52.64)			
SEC low vs. ETA				0.86 [0.27; 2.71] 0.801	0.93 [0.53; 1.64] 0.803	-0.04 [-0.33; 0.25] 0.799
SEC high vs. ETA				1.54 [0.48; 4.92] 0.470	1.20 [0.72; 2.00] 0.475	0.11 [-0.18; 0.39] 0.464
Baseline PASI > Median, N / N'	**29 / 26**	**29 / 27**	**19 / 16**			
n (%)	18.08 (62.34)	21.24 (73.24)	10.26 (54.00)			
SEC low vs. ETA				1.40 [0.42; 4.66] 0.582	1.15 [0.69; 1.94] 0.587	0.08 [-0.21; 0.38] 0.578
SEC high vs. ETA				2.29 [0.65; 8.06] 0.195	1.36 [0.83; 2.21] 0.219	0.19 [-0.09; 0.48] 0.187

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.5 CDLQI Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.661**					
Europe, N / N'	**39 / 38**	**46 / 43**	**24 / 21**			
n (%)	23.45 (60.13)	33.12 (72.00)	16.12 (67.17)			
SEC low vs. ETA				0.74 [0.25; 2.18] 0.584	0.90 [0.61; 1.32] 0.575	-0.07 [-0.32; 0.18] 0.576
SEC high vs. ETA				1.25 [0.42; 3.75] 0.687	1.07 [0.76; 1.51] 0.691	0.05 [-0.19; 0.28] 0.687
Others, N / N'	**17 / 14**	**12 / 11**	**17 / 14**			
n (%)	7.83 (46.06)	6.46 (53.83)	5.72 (33.65)			
SEC low vs. ETA				1.66 [0.40; 6.96] 0.486	1.37 [0.56; 3.33] 0.486	0.12 [-0.22; 0.47] 0.476
SEC high vs. ETA				2.24 [0.47; 10.64] 0.309	1.60 [0.66; 3.92] 0.300	0.20 [-0.17; 0.58] 0.292

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.6 CDLQI Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.835**					
Weight < 50 kg, N / N'	**28 / 27**	**26 / 24**	**20 / 17**			
n (%)	16.01 (57.18)	16.94 (65.15)	9.72 (48.60)			
SEC low vs. ETA				1.40 [0.44; 4.50] 0.570	1.18 [0.67; 2.08] 0.570	0.09 [-0.21; 0.38] 0.564
SEC high vs. ETA				1.95 [0.57; 6.67] 0.286	1.34 [0.77; 2.33] 0.298	0.17 [-0.13; 0.46] 0.274
Weight ≥ 50 kg, N / N'	**28 / 25**	**32 / 30**	**21 / 18**			
n (%)	15.27 (54.54)	22.64 (70.75)	12.12 (57.71)			
SEC low vs. ETA				0.88 [0.27; 2.83] 0.831	0.94 [0.56; 1.58] 0.828	-0.03 [-0.32; 0.26] 0.829
SEC high vs. ETA				1.75 [0.54; 5.67] 0.348	1.23 [0.79; 1.91] 0.364	0.13 [-0.14; 0.40] 0.345

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.7 CDLQI Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=56)	**SEC high (N=58)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response Week 52						
Interaction Test	**p=0.751**					
No previous systemic therapy, N / N'	**23 / 21**	**26 / 24**	**22 / 20**			
n (%)	14.07 (61.17)	17.94 (69.00)	13.56 (61.64)			
SEC low vs. ETA				0.98 [0.29; 3.37] 0.977	0.99 [0.61; 1.61] 0.974	-0.00 [-0.30; 0.29] 0.975
SEC high vs. ETA				1.38 [0.40; 4.72] 0.609	1.12 [0.72; 1.73] 0.611	0.07 [-0.21; 0.35] 0.606
Previous systemic therapy, N / N'	**33 / 31**	**32 / 30**	**19 / 15**			
n (%)	17.21 (52.15)	21.64 (67.63)	8.28 (43.58)			
SEC low vs. ETA				1.40 [0.44; 4.46] 0.566	1.20 [0.64; 2.24] 0.569	0.09 [-0.20; 0.37] 0.559
SEC high vs. ETA				2.65 [0.80; 8.84] 0.112	1.56 [0.86; 2.80] 0.142	0.24 [-0.05; 0.53] 0.099

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

11.1 CDLQI Response (Age ≤ 16) (FAS)

	Treatment Groups			Comparison		
	SEC low (N=35)	SEC high (N=39)	ETA (N=28)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
N'	34	36	24			
n (%)	24.14 (68.97)	25.78 (66.10)	14.29 (51.04)			
SEC low vs. ETA				2.11 [0.73; 6.07] 0.167	1.35 [0.87; 2.11] 0.182	0.18 [-0.07; 0.43] 0.158
SEC high vs. ETA				1.85 [0.66; 5.22] 0.242	1.30 [0.83; 2.03] 0.257	0.15 [-0.10; 0.40] 0.235

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.2 CDLQI Response (Age ≤ 16) by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=35)	SEC high (N=39)	ETA (N=28)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.962**					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 9**			
n (%)	8.00 (61.54)	7.41 (61.75)	4.28 (42.80)			
SEC low vs. ETA				2.07 [0.39; 11.09] 0.395	1.45 [0.61; 3.43] 0.403	0.19 [-0.23; 0.60] 0.375
SEC high vs. ETA				2.09 [0.37; 11.88] 0.405	1.45 [0.60; 3.49] 0.411	0.19 [-0.24; 0.62] 0.384
Age ≥ 12 years, N / N'	**22 / 21**	**27 / 25**	**18 / 15**			
n (%)	16.14 (73.36)	18.37 (68.04)	10.01 (55.61)			
SEC low vs. ETA				2.15 [0.55; 8.37] 0.268	1.32 [0.80; 2.20] 0.281	0.18 [-0.13; 0.48] 0.255
SEC high vs. ETA				1.68 [0.47; 6.02] 0.426	1.23 [0.73; 2.05] 0.437	0.12 [-0.18; 0.43] 0.420

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.3 CDLQI Response (Age ≤ 16) by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=35)	SEC high (N=39)	ETA (N=28)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.493**					
Male, N / N'	**9 / 9**	**16 / 15**	**10 / 7**			
n (%)	6.00 (66.67)	12.91 (80.69)	5.60 (56.00)			
SEC low vs. ETA				1.53 [0.23; 10.10] 0.661	1.20 [0.56; 2.55] 0.640	0.11 [-0.34; 0.56] 0.643
SEC high vs. ETA				3.12 [0.51; 19.12] 0.220	1.45 [0.76; 2.77] 0.260	0.25 [-0.14; 0.63] 0.208
Female, N / N'	**26 / 25**	**23 / 21**	**18 / 17**			
n (%)	18.14 (69.77)	12.87 (55.96)	8.69 (48.28)			
SEC low vs. ETA				2.42 [0.69; 8.51] 0.168	1.45 [0.83; 2.52] 0.192	0.21 [-0.08; 0.51] 0.155
SEC high vs. ETA				1.35 [0.38; 4.79] 0.640	1.16 [0.62; 2.16] 0.641	0.08 [-0.24; 0.39] 0.635

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.4 CDLQI Response (Age ≤ 16) by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=35)	SEC high (N=39)	ETA (N=28)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	p=0.728					
Baseline PASI ≤ Median, N / N'	15 / 15	23 / 21	13 / 11			
n (%)	11.00 (73.33)	14.37 (62.48)	6.00 (46.15)			
SEC low vs. ETA				3.07 [0.62; 15.30] 0.170	1.60 [0.79; 3.24] 0.193	0.27 [-0.09; 0.64] 0.145
SEC high vs. ETA				1.91 [0.45; 8.10] 0.379	1.36 [0.66; 2.79] 0.399	0.16 [-0.19; 0.52] 0.367
Baseline PASI > Median, N / N'	20 / 19	16 / 15	15 / 13			
n (%)	13.14 (65.70)	11.41 (71.31)	8.29 (55.27)			
SEC low vs. ETA				1.53 [0.38; 6.15] 0.548	1.19 [0.67; 2.11] 0.550	0.10 [-0.23; 0.44] 0.541
SEC high vs. ETA				1.97 [0.43; 8.96] 0.378	1.29 [0.73; 2.28] 0.379	0.16 [-0.18; 0.51] 0.362

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.5 CDLQI Response (Age ≤ 16) by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=35)	SEC high (N=39)	ETA (N=28)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.851**					
Europe, N / N'	**23 / 23**	**28 / 26**	**13 / 12**			
n (%)	18.00 (78.26)	20.32 (72.57)	9.31 (71.62)			
SEC low vs. ETA				1.40 [0.29; 6.83] 0.675	1.09 [0.72; 1.66] 0.672	0.07 [-0.24; 0.37] 0.669
SEC high vs. ETA				1.04 [0.23; 4.73] 0.957	1.01 [0.66; 1.56] 0.949	0.01 [-0.30; 0.32] 0.951
Others, N / N'	**12 / 11**	**11 / 10**	**15 / 12**			
n (%)	6.14 (51.17)	5.46 (49.64)	4.98 (33.20)			
SEC low vs. ETA				2.07 [0.41; 10.41] 0.379	1.56 [0.59; 4.12] 0.373	0.18 [-0.21; 0.57] 0.364
SEC high vs. ETA				1.94 [0.37; 10.18] 0.431	1.51 [0.55; 4.09] 0.423	0.16 [-0.23; 0.56] 0.418

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.6 CDLQI Response (Age ≤ 16) by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=35)	SEC high (N=39)	ETA (N=28)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.497**					
Weight < 50 kg, N / N'	**25 / 24**	**25 / 23**	**20 / 17**			
n (%)	15.14 (60.56)	15.87 (63.48)	9.98 (49.90)			
SEC low vs. ETA				1.53 [0.45; 5.17] 0.496	1.22 [0.69; 2.14] 0.497	0.11 [-0.20; 0.41] 0.489
SEC high vs. ETA				1.73 [0.50; 5.96] 0.388	1.27 [0.73; 2.23] 0.395	0.14 [-0.17; 0.44] 0.378
Weight ≥ 50 kg, N / N'	**10 / 10**	**14 / 13**	**8 / 7**			
n (%)	9.00 (90.00)	9.91 (70.79)	4.31 (53.88)			
SEC low vs. ETA				6.79 [0.58; 78.85] 0.126	1.68 [0.83; 3.42] 0.153	0.36 [-0.05; 0.77] 0.082
SEC high vs. ETA				2.00 [0.32; 12.50] 0.458	1.32 [0.62; 2.83] 0.474	0.17 [-0.27; 0.60] 0.446

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.7 CDLQI Response (Age ≤ 16) by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=35)	**SEC high (N=39)**	**ETA (N=28)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.814**					
No previous systemic therapy, N / N'	**16 / 16**	**17 / 15**	**17 / 16**			
n (%)	12.00 (75.00)	12.87 (75.71)	10.69 (62.88)			
SEC low vs. ETA				1.74 [0.39; 7.74] 0.469	1.19 [0.75; 1.91] 0.461	0.12 [-0.20; 0.44] 0.454
SEC high vs. ETA				1.83 [0.39; 8.62] 0.447	1.20 [0.75; 1.94] 0.446	0.13 [-0.19; 0.45] 0.434
Previous systemic therapy, N / N'	**19 / 18**	**22 / 21**	**11 / 8**			
n (%)	12.14 (63.89)	12.91 (58.68)	3.60 (32.73)			
SEC low vs. ETA				3.51 [0.68; 18.05] 0.132	1.98 [0.74; 5.33] 0.177	0.31 [-0.06; 0.68] 0.099
SEC high vs. ETA				2.85 [0.58; 13.98] 0.196	1.82 [0.67; 4.91] 0.238	0.26 [-0.10; 0.62] 0.161

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

Safety Analysis

S.1.1 Adverse Events, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
Any AE, n (%)	46 (82.1)	47 (81.0)	34 (82.9)			
SEC low vs. ETA				0.95 [0.28; 3.09] 1.000	0.99 [0.82; 1.19] 1.000	-0.01 [-0.16; 0.14] 0.920
SEC high vs. ETA				0.88 [0.26; 2.79] 1.000	0.98 [0.81; 1.18] 1.000	-0.02 [-0.17; 0.13] 0.809
Any AE, disease specific events excluded, n (%)	46 (82.1)	46 (79.3)	34 (82.9)			
SEC low vs. ETA				0.95 [0.28; 3.09] 1.000	0.99 [0.82; 1.19] 1.000	-0.01 [-0.16; 0.14] 0.920
SEC high vs. ETA				0.79 [0.24; 2.46] 0.856	0.96 [0.79; 1.16] 0.797	-0.04 [-0.19; 0.12] 0.648
Any SAE, n (%)	5 (8.9)	5 (8.6)	5 (12.2)			
SEC low vs. ETA				0.71 [0.15; 3.32] 0.844	0.73 [0.23; 2.36] 0.739	-0.03 [-0.16; 0.09] 0.608
SEC high vs. ETA				0.68 [0.15; 3.20] 0.798	0.71 [0.22; 2.29] 0.737	-0.04 [-0.16; 0.09] 0.571
Any SAE, disease specific events excluded, n (%)	5 (8.9)	5 (8.6)	5 (12.2)			
SEC low vs. ETA				0.71 [0.15; 3.32] 0.844	0.73 [0.23; 2.36] 0.739	-0.03 [-0.16; 0.09] 0.608
SEC high vs. ETA				0.68 [0.15; 3.20] 0.798	0.71 [0.22; 2.29] 0.737	-0.04 [-0.16; 0.09] 0.571
Any severe AE, n (%)	3 (5.4)	5 (8.6)	4 (9.8)			
SEC low vs. ETA				0.53 [0.07; 3.32] 0.659	0.55 [0.13; 2.32] 0.451	-0.04 [-0.15; 0.06] 0.426
SEC high vs. ETA				0.87 [0.17; 4.71] 1.000	0.88 [0.25; 3.09] 1.000	-0.01 [-0.13; 0.10] 0.848

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE, disease specific events excluded, n (%)	3 (5.4)	5 (8.6)	4 (9.8)			
SEC low vs. ETA				0.53 [0.07; 3.32] 0.659	0.55 [0.13; 2.32] 0.451	-0.04 [-0.15; 0.06] 0.426
SEC high vs. ETA				0.87 [0.17; 4.71] 1.000	0.88 [0.25; 3.09] 1.000	-0.01 [-0.13; 0.10] 0.848
Any AE leading to study discontinuation, n (%)	0 (0.0)	1 (1.7)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.71 [0.02; >999.99] 1.000	2.14 [0.09; 51.15] 1.000	0.02 [-0.02; 0.05] 0.313
Any AE leading to study drug discontinuation, n (%)	2 (3.6)	1 (1.7)	1 (2.4)			
SEC low vs. ETA				1.48 [0.07; 89.56] 1.000	1.46 [0.14; 15.61] 1.000	0.01 [-0.06; 0.08] 0.743
SEC high vs. ETA				0.70 [<0.01; 56.45] 1.000	0.71 [0.05; 10.98] 1.000	-0.01 [-0.07; 0.05] 0.809

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

List of Excluded Disease-Specific SOC/Preferred Terms

Preferred Terms (grouped by disease-specific event category)
General disorders and administration site conditions
Fatigue
Malaise
Musculoskeletal and connective tissue disorders
Arthralgia
Back pain
Joint swelling
Pain in extremity
Skin and subcutaneous tissue disorders
Dry skin
Erythema
Pruritus
Pruritus generalised
Psoriasis
Skin fissures
Skin irritation

S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
Any adverse event, n (%)	46 (82.1)	47 (81.0)	34 (82.9)			
SEC low vs. ETA				0.95 [0.28; 3.09] 1.000	0.99 [0.82; 1.19] 1.000	-0.01 [-0.16; 0.14] 0.920
SEC high vs. ETA				0.88 [0.26; 2.79] 1.000	0.98 [0.81; 1.18] 1.000	-0.02 [-0.17; 0.13] 0.809
Mild, n (%)	42 (75.0)	44 (75.9)	32 (78.0)			
SEC low vs. ETA				0.85 [0.28; 2.41] 0.920	0.96 [0.77; 1.20] 0.812	-0.03 [-0.20; 0.14] 0.725
SEC high vs. ETA				0.89 [0.30; 2.52] 0.996	0.97 [0.78; 1.21] 1.000	-0.02 [-0.19; 0.15] 0.798
Moderate, n (%)	22 (39.3)	24 (41.4)	19 (46.3)			
SEC low vs. ETA				0.75 [0.31; 1.83] 0.626	0.85 [0.53; 1.35] 0.536	-0.07 [-0.27; 0.13] 0.487
SEC high vs. ETA				0.82 [0.34; 1.98] 0.775	0.89 [0.57; 1.40] 0.683	-0.05 [-0.25; 0.15] 0.624
Severe, n (%)	3 (5.4)	5 (8.6)	4 (9.8)			
SEC low vs. ETA				0.53 [0.07; 3.32] 0.659	0.55 [0.13; 2.32] 0.451	-0.04 [-0.15; 0.06] 0.426
SEC high vs. ETA				0.87 [0.17; 4.71] 1.000	0.88 [0.25; 3.09] 1.000	-0.01 [-0.13; 0.10] 0.848
Infections and infestations, n (%)	40 (71.4)	38 (65.5)	27 (65.9)			
SEC low vs. ETA				1.29 [0.49; 3.36] 0.713	1.08 [0.82; 1.43] 0.658	0.06 [-0.13; 0.24] 0.560
SEC high vs. ETA				0.99 [0.39; 2.47] 1.000	0.99 [0.75; 1.33] 1.000	-0.00 [-0.19; 0.19] 0.972

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	35 (62.5)	36 (62.1)	25 (61.0)			
SEC low vs. ETA				1.07 [0.43; 2.64] 1.000	1.03 [0.75; 1.41] 1.000	0.02 [-0.18; 0.21] 0.879
SEC high vs. ETA				1.05 [0.42; 2.57] 1.000	1.02 [0.74; 1.40] 1.000	0.01 [-0.18; 0.21] 0.912
Moderate, n (%)	15 (26.8)	18 (31.0)	10 (24.4)			
SEC low vs. ETA				1.13 [0.41; 3.23] 0.980	1.10 [0.55; 2.19] 0.819	0.02 [-0.15; 0.20] 0.789
SEC high vs. ETA				1.39 [0.52; 3.88] 0.623	1.27 [0.66; 2.47] 0.505	0.07 [-0.11; 0.24] 0.463
Severe, n (%)	3 (5.4)	4 (6.9)	1 (2.4)			
SEC low vs. ETA				2.25 [0.17; 121.78] 0.868	2.20 [0.24; 20.37] 0.636	0.03 [-0.05; 0.10] 0.449
SEC high vs. ETA				2.94 [0.28; 149.50] 0.615	2.83 [0.33; 24.39] 0.400	0.04 [-0.04; 0.13] 0.278
Nasopharyngitis, n (%)	14 (25.0)	20 (34.5)	11 (26.8)			
SEC low vs. ETA				0.91 [0.33; 2.55] 1.000	0.93 [0.47; 1.84] 1.000	-0.02 [-0.20; 0.16] 0.839
SEC high vs. ETA				1.43 [0.55; 3.85] 0.559	1.29 [0.69; 2.38] 0.511	0.08 [-0.11; 0.26] 0.411
Mild, n (%)	13 (23.2)	17 (29.3)	10 (24.4)			
SEC low vs. ETA				0.94 [0.33; 2.73] 1.000	0.95 [0.46; 1.95] 1.000	-0.01 [-0.18; 0.16] 0.893
SEC high vs. ETA				1.28 [0.48; 3.60] 0.759	1.20 [0.61; 2.35] 0.652	0.05 [-0.13; 0.23] 0.584
Moderate, n (%)	2 (3.6)	5 (8.6)	2 (4.9)			
SEC low vs. ETA				0.72 [0.05; 10.40] 1.000	0.73 [0.11; 4.98] 1.000	-0.01 [-0.09; 0.07] 0.755
SEC high vs. ETA				1.83 [0.28; 20.16] 0.768	1.77 [0.36; 8.67] 0.696	0.04 [-0.06; 0.14] 0.453

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Pharyngitis, n (%)	7 (12.5)	7 (12.1)	3 (7.3)			
SEC low vs. ETA				1.80 [0.38; 11.49] 0.633	1.71 [0.47; 6.21] 0.511	0.05 [-0.07; 0.17] 0.388
SEC high vs. ETA				1.73 [0.36; 11.04] 0.676	1.65 [0.45; 6.00] 0.516	0.05 [-0.07; 0.16] 0.421
Mild, n (%)	4 (7.1)	6 (10.3)	1 (2.4)			
SEC low vs. ETA				3.05 [0.29; 155.25] 0.586	2.93 [0.34; 25.24] 0.393	0.05 [-0.04; 0.13] 0.263
SEC high vs. ETA				4.56 [0.52; 217.50] 0.263	4.24 [0.53; 33.91] 0.234	0.08 [-0.01; 0.17] 0.090
Moderate, n (%)	2 (3.6)	1 (1.7)	1 (2.4)			
SEC low vs. ETA				1.48 [0.07; 89.56] 1.000	1.46 [0.14; 15.61] 1.000	0.01 [-0.06; 0.08] 0.743
SEC high vs. ETA				0.70 [<0.01; 56.45] 1.000	0.71 [0.05; 10.98] 1.000	-0.01 [-0.07; 0.05] 0.809
Severe, n (%)	1 (1.8)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 58.50] 1.000	0.73 [0.05; 11.37] 1.000	-0.01 [-0.07; 0.05] 0.827
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311
Rhinitis, n (%)	4 (7.1)	7 (12.1)	1 (2.4)			
SEC low vs. ETA				3.05 [0.29; 155.25] 0.586	2.93 [0.34; 25.24] 0.393	0.05 [-0.04; 0.13] 0.263
SEC high vs. ETA				5.42 [0.65; 253.50] 0.166	4.95 [0.63; 38.70] 0.135	0.10 [0.00; 0.19] 0.050
Mild, n (%)	3 (5.4)	7 (12.1)	1 (2.4)			
SEC low vs. ETA				2.25 [0.17; 121.78] 0.868	2.20 [0.24; 20.37] 0.636	0.03 [-0.05; 0.10] 0.449
SEC high vs. ETA				5.42 [0.65; 253.50] 0.166	4.95 [0.63; 38.70] 0.135	0.10 [0.00; 0.19] 0.050

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	1 (1.8)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Upper respiratory tract infection, n (%)	7 (12.5)	2 (3.4)	3 (7.3)			
SEC low vs. ETA				1.80 [0.38; 11.49] 0.633	1.71 [0.47; 6.21] 0.511	0.05 [-0.07; 0.17] 0.388
SEC high vs. ETA				0.46 [0.04; 4.18] 0.678	0.47 [0.08; 2.70] 0.646	-0.04 [-0.13; 0.05] 0.412
Mild, n (%)	5 (8.9)	1 (1.7)	3 (7.3)			
SEC low vs. ETA				1.24 [0.22; 8.47] 1.000	1.22 [0.31; 4.82] 1.000	0.02 [-0.09; 0.13] 0.772
SEC high vs. ETA				0.23 [<0.01; 2.93] 0.382	0.24 [0.03; 2.19] 0.304	-0.06 [-0.14; 0.03] 0.205
Moderate, n (%)	3 (5.4)	1 (1.7)	0 (0.0)			
SEC low vs. ETA				2.90 [0.30; >999.99] 0.376	5.16 [0.27; 97.21] 0.260	0.05 [-0.01; 0.11] 0.075
SEC high vs. ETA				0.71 [0.02; >999.99] 1.000	2.14 [0.09; 51.15] 1.000	0.02 [-0.02; 0.05] 0.313
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Gastrointestinal disorders, n (%)	17 (30.4)	19 (32.8)	14 (34.1)			
SEC low vs. ETA				0.84 [0.33; 2.19] 0.858	0.89 [0.50; 1.59] 0.826	-0.04 [-0.23; 0.15] 0.694
SEC high vs. ETA				0.94 [0.37; 2.41] 1.000	0.96 [0.55; 1.68] 1.000	-0.01 [-0.20; 0.17] 0.885

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	16 (28.6)	17 (29.3)	8 (19.5)			
SEC low vs. ETA				1.64 [0.58; 5.02] 0.435	1.46 [0.69; 3.09] 0.349	0.09 [-0.08; 0.26] 0.295
SEC high vs. ETA				1.70 [0.60; 5.16] 0.385	1.50 [0.72; 3.15] 0.349	0.10 [-0.07; 0.27] 0.255
Moderate, n (%)	3 (5.4)	4 (6.9)	6 (14.6)			
SEC low vs. ETA				0.33 [0.05; 1.69] 0.231	0.37 [0.10; 1.38] 0.161	-0.09 [-0.22; 0.03] 0.140
SEC high vs. ETA				0.44 [0.08; 1.99] 0.357	0.47 [0.14; 1.57] 0.311	-0.08 [-0.20; 0.05] 0.230
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 28.55] 0.845	0.25 [0.01; 5.88] 0.423	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311
Abdominal pain, n (%)	3 (5.4)	5 (8.6)	5 (12.2)			
SEC low vs. ETA				0.41 [0.06; 2.27] 0.402	0.44 [0.11; 1.73] 0.277	-0.07 [-0.18; 0.05] 0.249
SEC high vs. ETA				0.68 [0.15; 3.20] 0.798	0.71 [0.22; 2.29] 0.737	-0.04 [-0.16; 0.09] 0.571
Mild, n (%)	2 (3.6)	5 (8.6)	3 (7.3)			
SEC low vs. ETA				0.47 [0.04; 4.34] 0.709	0.49 [0.09; 2.79] 0.647	-0.04 [-0.13; 0.06] 0.432
SEC high vs. ETA				1.19 [0.22; 8.15] 1.000	1.18 [0.30; 4.66] 1.000	0.01 [-0.09; 0.12] 0.812
Moderate, n (%)	1 (1.8)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 58.50] 1.000	0.73 [0.05; 11.37] 1.000	-0.01 [-0.07; 0.05] 0.827
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 28.55] 0.845	0.25 [0.01; 5.88] 0.423	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311
Skin and subcutaneous tissue disorders, n (%)	15 (26.8)	17 (29.3)	10 (24.4)			
SEC low vs. ETA				1.13 [0.41; 3.23] 0.980	1.10 [0.55; 2.19] 0.819	0.02 [-0.15; 0.20] 0.789
SEC high vs. ETA				1.28 [0.48; 3.60] 0.759	1.20 [0.61; 2.35] 0.652	0.05 [-0.13; 0.23] 0.584
Mild, n (%)	14 (25.0)	13 (22.4)	7 (17.1)			
SEC low vs. ETA				1.61 [0.53; 5.28] 0.495	1.46 [0.65; 3.30] 0.456	0.08 [-0.08; 0.24] 0.336
SEC high vs. ETA				1.40 [0.46; 4.61] 0.697	1.31 [0.57; 3.00] 0.615	0.05 [-0.10; 0.21] 0.506
Moderate, n (%)	3 (5.4)	7 (12.1)	2 (4.9)			
SEC low vs. ETA				1.10 [0.12; 13.79] 1.000	1.10 [0.19; 6.28] 1.000	0.00 [-0.08; 0.09] 0.915
SEC high vs. ETA				2.65 [0.47; 27.55] 0.388	2.47 [0.54; 11.31] 0.299	0.07 [-0.03; 0.18] 0.186
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 28.55] 0.845	0.25 [0.01; 5.88] 0.423	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311
General disorders and administration site conditions, n (%)	10 (17.9)	14 (24.1)	8 (19.5)			
SEC low vs. ETA				0.90 [0.28; 2.92] 1.000	0.92 [0.40; 2.12] 1.000	-0.02 [-0.17; 0.14] 0.837
SEC high vs. ETA				1.31 [0.45; 4.05] 0.770	1.24 [0.57; 2.67] 0.632	0.05 [-0.12; 0.21] 0.580

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	9 (16.1)	11 (19.0)	7 (17.1)			
SEC low vs. ETA				0.93 [0.28; 3.26] 1.000	0.94 [0.38; 2.32] 1.000	-0.01 [-0.16; 0.14] 0.896
SEC high vs. ETA				1.14 [0.36; 3.83] 1.000	1.11 [0.47; 2.62] 1.000	0.02 [-0.13; 0.17] 0.809
Moderate, n (%)	1 (1.8)	2 (3.4)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 58.50] 1.000	0.73 [0.05; 11.37] 1.000	-0.01 [-0.07; 0.05] 0.827
SEC high vs. ETA				1.42 [0.07; 86.36] 1.000	1.41 [0.13; 15.08] 1.000	0.01 [-0.06; 0.08] 0.766
Severe, n (%)	0 (0.0)	1 (1.7)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.71 [0.02; >999.99] 1.000	2.14 [0.09; 51.15] 1.000	0.02 [-0.02; 0.05] 0.313
Respiratory, thoracic and mediastinal disorders, n (%)	9 (16.1)	13 (22.4)	4 (9.8)			
SEC low vs. ETA				1.76 [0.45; 8.46] 0.555	1.65 [0.54; 4.98] 0.548	0.06 [-0.07; 0.20] 0.349
SEC high vs. ETA				2.65 [0.74; 12.10] 0.165	2.30 [0.81; 6.54] 0.114	0.13 [-0.01; 0.27] 0.078
Mild, n (%)	7 (12.5)	12 (20.7)	4 (9.8)			
SEC low vs. ETA				1.32 [0.31; 6.61] 0.934	1.28 [0.40; 4.09] 0.755	0.03 [-0.10; 0.15] 0.668
SEC high vs. ETA				2.39 [0.65; 11.03] 0.236	2.12 [0.74; 6.11] 0.175	0.11 [-0.03; 0.25] 0.121
Moderate, n (%)	1 (1.8)	2 (3.4)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				1.73 [0.13; >999.99] 0.682	3.56 [0.18; 72.25] 0.510	0.03 [-0.01; 0.08] 0.150

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	1 (1.8)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				N.E.	N.E.	N.E.
Nervous system disorders, n (%)	10 (17.9)	9 (15.5)	4 (9.8)			
SEC low vs. ETA				2.00 [0.52; 9.44] 0.410	1.83 [0.62; 5.43] 0.382	0.08 [-0.05; 0.22] 0.241
SEC high vs. ETA				1.69 [0.43; 8.10] 0.602	1.59 [0.53; 4.82] 0.549	0.06 [-0.07; 0.19] 0.386
Mild, n (%)	9 (16.1)	8 (13.8)	3 (7.3)			
SEC low vs. ETA				2.41 [0.55; 14.77] 0.327	2.20 [0.63; 7.61] 0.229	0.09 [-0.04; 0.21] 0.170
SEC high vs. ETA				2.01 [0.44; 12.57] 0.500	1.89 [0.53; 6.68] 0.354	0.06 [-0.05; 0.18] 0.287
Moderate, n (%)	1 (1.8)	1 (1.7)	2 (4.9)			
SEC low vs. ETA				0.36 [<0.01; 7.11] 0.767	0.37 [0.03; 3.90] 0.572	-0.03 [-0.11; 0.04] 0.416
SEC high vs. ETA				0.35 [<0.01; 6.86] 0.742	0.35 [0.03; 3.77] 0.568	-0.03 [-0.11; 0.04] 0.403
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Headache, n (%)	8 (14.3)	9 (15.5)	4 (9.8)			
SEC low vs. ETA				1.54 [0.38; 7.51] 0.731	1.46 [0.47; 4.54] 0.551	0.05 [-0.08; 0.17] 0.491
SEC high vs. ETA				1.69 [0.43; 8.10] 0.602	1.59 [0.53; 4.82] 0.549	0.06 [-0.07; 0.19] 0.386
Mild, n (%)	8 (14.3)	8 (13.8)	3 (7.3)			
SEC low vs. ETA				2.10 [0.46; 13.10] 0.462	1.95 [0.55; 6.91] 0.347	0.07 [-0.05; 0.19] 0.261
SEC high vs. ETA				2.01 [0.44; 12.57] 0.500	1.89 [0.53; 6.68] 0.354	0.06 [-0.05; 0.18] 0.287

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	0 (0.0)	1 (1.7)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 28.55] 0.845	0.25 [0.01; 5.88] 0.423	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				0.70 [<0.01; 56.45] 1.000	0.71 [0.05; 10.98] 1.000	-0.01 [-0.07; 0.05] 0.809
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Injury, poisoning and procedural complications, n (%)	4 (7.1)	7 (12.1)	1 (2.4)			
SEC low vs. ETA				3.05 [0.29; 155.25] 0.586	2.93 [0.34; 25.24] 0.393	0.05 [-0.04; 0.13] 0.263
SEC high vs. ETA				5.42 [0.65; 253.50] 0.166	4.95 [0.63; 38.70] 0.135	0.10 [0.00; 0.19] 0.050
Mild, n (%)	4 (7.1)	6 (10.3)	0 (0.0)			
SEC low vs. ETA				4.05 [0.49; >999.99] 0.212	6.63 [0.37; 119.86] 0.135	0.07 [0.00; 0.14] 0.038
SEC high vs. ETA				6.24 [0.87; >999.99] 0.072	9.25 [0.54; 159.85] 0.040	0.10 [0.03; 0.18] 0.010
Moderate, n (%)	0 (0.0)	2 (3.4)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 28.55] 0.845	0.25 [0.01; 5.88] 0.423	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				1.42 [0.07; 86.36] 1.000	1.41 [0.13; 15.08] 1.000	0.01 [-0.06; 0.08] 0.766
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Musculoskeletal and connective tissue disorders, n (%)	4 (7.1)	7 (12.1)	5 (12.2)			
SEC low vs. ETA				0.56 [0.10; 2.79] 0.616	0.59 [0.17; 2.05] 0.487	-0.05 [-0.17; 0.07] 0.412
SEC high vs. ETA				0.99 [0.25; 4.28] 1.000	0.99 [0.34; 2.90] 1.000	-0.00 [-0.13; 0.13] 0.985
Mild, n (%)	2 (3.6)	5 (8.6)	4 (9.8)			
SEC low vs. ETA				0.35 [0.03; 2.56] 0.410	0.37 [0.07; 1.90] 0.238	-0.06 [-0.16; 0.04] 0.239
SEC high vs. ETA				0.87 [0.17; 4.71] 1.000	0.88 [0.25; 3.09] 1.000	-0.01 [-0.13; 0.10] 0.848
Moderate, n (%)	2 (3.6)	2 (3.4)	1 (2.4)			
SEC low vs. ETA				1.48 [0.07; 89.56] 1.000	1.46 [0.14; 15.61] 1.000	0.01 [-0.06; 0.08] 0.743
SEC high vs. ETA				1.42 [0.07; 86.36] 1.000	1.41 [0.13; 15.08] 1.000	0.01 [-0.06; 0.08] 0.766
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Blood and lymphatic system disorders, n (%)	6 (10.7)	3 (5.2)	2 (4.9)			
SEC low vs. ETA				2.32 [0.39; 24.74] 0.520	2.20 [0.47; 10.34] 0.461	0.06 [-0.05; 0.16] 0.273
SEC high vs. ETA				1.06 [0.12; 13.29] 1.000	1.06 [0.19; 6.07] 1.000	0.00 [-0.08; 0.09] 0.947
Mild, n (%)	4 (7.1)	3 (5.2)	1 (2.4)			
SEC low vs. ETA				3.05 [0.29; 155.25] 0.586	2.93 [0.34; 25.24] 0.393	0.05 [-0.04; 0.13] 0.263
SEC high vs. ETA				2.17 [0.17; 117.36] 0.898	2.12 [0.23; 19.67] 0.640	0.03 [-0.05; 0.10] 0.469

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	2 (3.6)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				1.48 [0.07; 89.56] 1.000	1.46 [0.14; 15.61] 1.000	0.01 [-0.06; 0.08] 0.743
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311
Severe, n (%)	0 (0.0)	1 (1.7)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.71 [0.02; >999.99] 1.000	2.14 [0.09; 51.15] 1.000	0.02 [-0.02; 0.05] 0.313
Investigations, n (%)	5 (8.9)	4 (6.9)	6 (14.6)			
SEC low vs. ETA				0.58 [0.13; 2.46] 0.577	0.61 [0.20; 1.86] 0.519	-0.06 [-0.19; 0.07] 0.395
SEC high vs. ETA				0.44 [0.08; 1.99] 0.357	0.47 [0.14; 1.57] 0.311	-0.08 [-0.20; 0.05] 0.230
Mild, n (%)	5 (8.9)	2 (3.4)	3 (7.3)			
SEC low vs. ETA				1.24 [0.22; 8.47] 1.000	1.22 [0.31; 4.82] 1.000	0.02 [-0.09; 0.13] 0.772
SEC high vs. ETA				0.46 [0.04; 4.18] 0.678	0.47 [0.08; 2.70] 0.646	-0.04 [-0.13; 0.05] 0.412
Moderate, n (%)	2 (3.6)	2 (3.4)	4 (9.8)			
SEC low vs. ETA				0.35 [0.03; 2.56] 0.410	0.37 [0.07; 1.90] 0.238	-0.06 [-0.16; 0.04] 0.239
SEC high vs. ETA				0.33 [0.03; 2.47] 0.384	0.35 [0.07; 1.84] 0.228	-0.06 [-0.17; 0.04] 0.227
Severe, n (%)	0 (0.0)	1 (1.7)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.71 [0.02; >999.99] 1.000	2.14 [0.09; 51.15] 1.000	0.02 [-0.02; 0.05] 0.313

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Reproductive system and breast disorders, n (%)	4 (7.1)	6 (10.3)	3 (7.3)			
SEC low vs. ETA				0.97 [0.15; 7.04] 1.000	0.98 [0.23; 4.13] 1.000	-0.00 [-0.11; 0.10] 0.974
SEC high vs. ETA				1.46 [0.29; 9.56] 0.886	1.41 [0.38; 5.33] 0.732	0.03 [-0.08; 0.14] 0.596
Mild, n (%)	3 (5.4)	6 (10.3)	3 (7.3)			
SEC low vs. ETA				0.72 [0.09; 5.67] 1.000	0.73 [0.16; 3.45] 0.695	-0.02 [-0.12; 0.08] 0.698
SEC high vs. ETA				1.46 [0.29; 9.56] 0.886	1.41 [0.38; 5.33] 0.732	0.03 [-0.08; 0.14] 0.596
Moderate, n (%)	1 (1.8)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.1.3 Serious Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
Any SAE, n (%)	5 (8.9)	5 (8.6)	5 (12.2)			
SEC low vs. ETA				0.71 [0.15; 3.32] 0.844	0.73 [0.23; 2.36] 0.739	-0.03 [-0.16; 0.09] 0.608
SEC high vs. ETA				0.68 [0.15; 3.20] 0.798	0.71 [0.22; 2.29] 0.737	-0.04 [-0.16; 0.09] 0.571
Mild, n (%)	1 (1.8)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	3 (5.4)	1 (1.7)	3 (7.3)			
SEC low vs. ETA				0.72 [0.09; 5.67] 1.000	0.73 [0.16; 3.45] 0.695	-0.02 [-0.12; 0.08] 0.698
SEC high vs. ETA				0.23 [<0.01; 2.93] 0.382	0.24 [0.03; 2.19] 0.304	-0.06 [-0.14; 0.03] 0.205
Severe, n (%)	1 (1.8)	4 (6.9)	3 (7.3)			
SEC low vs. ETA				0.23 [<0.01; 3.04] 0.403	0.24 [0.03; 2.26] 0.308	-0.06 [-0.14; 0.03] 0.212
SEC high vs. ETA				0.94 [0.15; 6.78] 1.000	0.94 [0.22; 3.99] 1.000	-0.00 [-0.11; 0.10] 0.936
Gastrointestinal disorders, n (%)	0 (0.0)	0 (0.0)	3 (7.3)			
SEC low vs. ETA				0.18 [<0.01; 1.74] 0.145	0.11 [0.01; 1.98] 0.072	-0.07 [-0.15; 0.01] 0.072
SEC high vs. ETA				0.18 [<0.01; 1.68] 0.136	0.10 [0.01; 1.92] 0.068	-0.07 [-0.15; 0.01] 0.072
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	0 (0.0)	0 (0.0)	2 (4.9)			
SEC low vs. ETA				0.30 [<0.01; 3.87] 0.352	0.15 [0.01; 2.99] 0.176	-0.05 [-0.11; 0.02] 0.147
SEC high vs. ETA				0.29 [<0.01; 3.74] 0.338	0.14 [0.01; 2.89] 0.169	-0.05 [-0.11; 0.02] 0.147
Severe, n (%)	0 (0.0)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 28.55] 0.845	0.25 [0.01; 5.88] 0.423	-0.02 [-0.07; 0.02] 0.311
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311
Infections and infestations, n (%)	1 (1.8)	3 (5.2)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				2.79 [0.29; >999.99] 0.393	4.98 [0.26; 93.95] 0.265	0.05 [-0.01; 0.11] 0.075
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	1 (1.8)	3 (5.2)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				2.79 [0.29; >999.99] 0.393	4.98 [0.26; 93.95] 0.265	0.05 [-0.01; 0.11] 0.075

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S1.4 Any AE Leading to Study Discontinuation

Patient ID	Actual Treat-ment	Reported term/ Preferred term/ System organ class	Start Date/Day End Date/Day Date/Day of study discontinuation	Serious	Severity/ Causality/ Action taken[1]
1500005	SEC high	TOXIC SHOCK SYNDROME/ Toxic shock syndrome/ Infections and infestations	2018-06-21 / 16 2018-07-18 / 43 2018-11-28 / 176	Y	SEV/ NO/ withdrawn
		right calf abcess/ Abscess limb/ Infections and infestations	2018-07-06 / 31 2018-07-18 / 43 2018-11-28 / 176	N	MILD/ NO/ na
[1] not changed = DOSE NOT CHANGED, withdrawn = DRUG WITHDRAWN, na = NOT APPLICABLE					

S1.5 Any AE Leading to Study Drug Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)
N'	56	58	41
Infections and infestations, n (%)	0 (0.0)	1 (1.7)	0 (0.0)
Toxic shock syndrome, n (%)	0 (0.0)	1 (1.7)	0 (0.0)
Investigations, n (%)	0 (0.0)	0 (0.0)	1 (2.4)
Hepatic enzyme increased, n (%)	0 (0.0)	0 (0.0)	1 (2.4)
Musculoskeletal and connective tissue disorders, n (%)	1 (1.8)	0 (0.0)	0 (0.0)
Arthritis reactive, n (%)	1 (1.8)	0 (0.0)	0 (0.0)
Psychiatric disorders, n (%)	1 (1.8)	0 (0.0)	0 (0.0)
Behaviour disorder, n (%)	1 (1.8)	0 (0.0)	0 (0.0)
Major depression, n (%)	1 (1.8)	0 (0.0)	0 (0.0)
Mental disorder, n (%)	1 (1.8)	0 (0.0)	0 (0.0)
Suicidal ideation, n (%)	1 (1.8)	0 (0.0)	0 (0.0)
N': Number of patients in the analysis n (%): Number and percentage of patients with event			

S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
Infections and infestations (SOC), n (%)	40 (71.4)	39 (67.2)	27 (65.9)			
SEC low vs. ETA				1.29 [0.49; 3.36] 0.713	1.08 [0.82; 1.43] 0.658	0.06 [-0.13; 0.24] 0.560
SEC high vs. ETA				1.06 [0.42; 2.69] 1.000	1.02 [0.77; 1.36] 1.000	0.01 [-0.17; 0.20] 0.885
Mild, n (%)	35 (62.5)	37 (63.8)	25 (61.0)			
SEC low vs. ETA				1.07 [0.43; 2.64] 1.000	1.03 [0.75; 1.41] 1.000	0.02 [-0.18; 0.21] 0.879
SEC high vs. ETA				1.13 [0.45; 2.78] 0.938	1.05 [0.77; 1.43] 0.834	0.03 [-0.17; 0.22] 0.776
Moderate, n (%)	15 (26.8)	18 (31.0)	10 (24.4)			
SEC low vs. ETA				1.13 [0.41; 3.23] 0.980	1.10 [0.55; 2.19] 0.819	0.02 [-0.15; 0.20] 0.789
SEC high vs. ETA				1.39 [0.52; 3.88] 0.623	1.27 [0.66; 2.47] 0.505	0.07 [-0.11; 0.24] 0.463
Severe, n (%)	3 (5.4)	4 (6.9)	1 (2.4)			
SEC low vs. ETA				2.25 [0.17; 121.78] 0.868	2.20 [0.24; 20.37] 0.636	0.03 [-0.05; 0.10] 0.449
SEC high vs. ETA				2.94 [0.28; 149.50] 0.615	2.83 [0.33; 24.39] 0.400	0.04 [-0.04; 0.13] 0.278
Serious, n (%)	2 (3.6)	3 (5.2)	0 (0.0)			
SEC low vs. ETA				1.79 [0.14; >999.99] 0.662	3.68 [0.18; 74.75] 0.507	0.04 [-0.01; 0.08] 0.150
SEC high vs. ETA				2.79 [0.29; >999.99] 0.393	4.98 [0.26; 93.95] 0.265	0.05 [-0.01; 0.11] 0.075

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Hypersensitivity (SMQ) (narrow), n (%)	5 (8.9)	11 (19.0)	5 (12.2)			
SEC low vs. ETA				0.71 [0.15; 3.32] 0.844	0.73 [0.23; 2.36] 0.739	-0.03 [-0.16; 0.09] 0.608
SEC high vs. ETA				1.68 [0.48; 6.72] 0.538	1.56 [0.58; 4.14] 0.419	0.07 [-0.07; 0.21] 0.351
Mild, n (%)	5 (8.9)	7 (12.1)	5 (12.2)			
SEC low vs. ETA				0.71 [0.15; 3.32] 0.844	0.73 [0.23; 2.36] 0.739	-0.03 [-0.16; 0.09] 0.608
SEC high vs. ETA				0.99 [0.25; 4.28] 1.000	0.99 [0.34; 2.90] 1.000	-0.00 [-0.13; 0.13] 0.985
Moderate, n (%)	0 (0.0)	5 (8.6)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				5.05 [0.67; >999.99] 0.128	7.83 [0.44; 137.82] 0.075	0.09 [0.01; 0.16] 0.019
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Neutropenia (NMQ) (narrow), n (%)	2 (3.6)	1 (1.7)	1 (2.4)			
SEC low vs. ETA				1.48 [0.07; 89.56] 1.000	1.46 [0.14; 15.61] 1.000	0.01 [-0.06; 0.08] 0.743
SEC high vs. ETA				0.70 [<0.01; 56.45] 1.000	0.71 [0.05; 10.98] 1.000	-0.01 [-0.07; 0.05] 0.809
Mild, n (%)	1 (1.8)	1 (1.7)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.21 [0.09; 52.93] 1.000	0.02 [-0.02; 0.05] 0.313
SEC high vs. ETA				0.71 [0.02; >999.99] 1.000	2.14 [0.09; 51.15] 1.000	0.02 [-0.02; 0.05] 0.313

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	1 (1.8)	0 (0.0)	1 (2.4)			
SEC low vs. ETA				0.73 [<0.01; 58.50] 1.000	0.73 [0.05; 11.37] 1.000	-0.01 [-0.07; 0.05] 0.827
SEC high vs. ETA				0.71 [<0.01; 27.57] 0.828	0.24 [0.01; 5.68] 0.414	-0.02 [-0.07; 0.02] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

Die Diskrepanz in der Häufigkeit der Ereignisse in der SOC Infections and Investigations im Vergleich zu S.1.2 erklärt sich folgendermaßen: In S.1.2. (UE nach SOC und PT) wird die Primary SOC verwendet wird, während in S.1.6. auch Events zur SOC Infections and infestations zugeordnet werden, die zwar auch zu dieser SOC gehören, aber primär einer anderen SOC zugeordnet sind. Konkret handelt es sich dabei um das AE ‚Virus warts' in der Gruppe SEC high (PT: Skin papilloma, Primary SOC: Neoplasms benign, malignant and unspecified, Secondary SOCs: Skin and subcutaneous tissue disorders / Infections and infestations).

S.1.7 Tanner Stage, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
N'	56	57	40			
n (%)	51 (91.1)	42 (73.7)	35 (87.5)			
SEC low vs. ETA				1.45 [0.31; 6.82] 0.811	1.04 [0.90; 1.20] 0.737	0.04 [-0.09; 0.16] 0.581
SEC high vs. ETA				0.40 [0.10; 1.32] 0.158	0.84 [0.69; 1.02] 0.128	-0.14 [-0.29; 0.02] 0.078
Pubertal at Week 52						
N'	54	53	36			
n (%)	51 (94.4)	43 (81.1)	34 (94.4)			
SEC low vs. ETA				1.00 [0.08; 9.21] 1.000	1.00 [0.90; 1.11] 1.000	0.00 [-0.10; 0.10] 1.000
SEC high vs. ETA				0.26 [0.03; 1.32] 0.129	0.86 [0.74; 1.00] 0.113	-0.13 [-0.26; -0.00] 0.043

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.2.1 Adverse Events, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Age < 12 years	13	12	10			
N' Age ≥ 12 years	43	46	31			
Any AE						
Interaction test:	p=0.726					
Age < 12 years, n (%)	11 (84.6)	9 (75.0)	7 (70.0)			
SEC low vs. ETA				2.27 [0.20; 33.80] 0.734	1.21 [0.76; 1.93] 0.618	0.15 [-0.20; 0.49] 0.407
SEC high vs. ETA				1.27 [0.13; 12.73] 1.000	1.07 [0.64; 1.80] 1.000	0.05 [-0.33; 0.43] 0.794
Age ≥ 12 years, n (%)	35 (81.4)	38 (82.6)	27 (87.1)			
SEC low vs. ETA				0.65 [0.13; 2.75] 0.746	0.93 [0.77; 1.14] 0.750	-0.06 [-0.22; 0.11] 0.500
SEC high vs. ETA				0.71 [0.14; 2.97] 0.844	0.95 [0.78; 1.15] 0.753	-0.04 [-0.21; 0.12] 0.585
Any SAE						
Interaction test:	p=0.582					
Age < 12 years, n (%)	1 (7.7)	2 (16.7)	1 (10.0)			
SEC low vs. ETA				0.76 [<0.01; 65.34] 1.000	0.77 [0.05; 10.85] 1.000	-0.02 [-0.26; 0.21] 0.848
SEC high vs. ETA				1.75 [0.08; 117.81] 1.000	1.67 [0.18; 15.80] 1.000	0.07 [-0.21; 0.35] 0.642
Age ≥ 12 years, n (%)	4 (9.3)	3 (6.5)	4 (12.9)			
SEC low vs. ETA				0.70 [0.12; 4.08] 0.898	0.72 [0.20; 2.66] 0.713	-0.04 [-0.18; 0.11] 0.630
SEC high vs. ETA				0.48 [0.06; 3.05] 0.574	0.51 [0.12; 2.10] 0.430	-0.06 [-0.20; 0.07] 0.364

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.694					
Age < 12 years, n (%)	0 (0.0)	2 (16.7)	1 (10.0)			
SEC low vs. ETA				0.77 [<0.01; 30.00] 0.870	0.26 [0.01; 5.82] 0.435	-0.10 [-0.29; 0.09] 0.292
SEC high vs. ETA				1.75 [0.08; 117.81] 1.000	1.67 [0.18; 15.80] 1.000	0.07 [-0.21; 0.35] 0.642
Age ≥ 12 years, n (%)	3 (7.0)	3 (6.5)	3 (9.7)			
SEC low vs. ETA				0.70 [0.09; 5.64] 0.992	0.72 [0.16; 3.34] 0.690	-0.03 [-0.16; 0.10] 0.681
SEC high vs. ETA				0.65 [0.08; 5.24] 0.922	0.67 [0.15; 3.13] 0.680	-0.03 [-0.16; 0.09] 0.624
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	1 (8.3)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.83 [0.02; >999.99] 1.000	2.54 [0.11; 56.25] 1.000	0.08 [-0.07; 0.24] 0.296
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.217					
Age < 12 years, n (%)	0 (0.0)	1 (8.3)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.83 [0.02; >999.99] 1.000	2.54 [0.11; 56.25] 1.000	0.08 [-0.07; 0.24] 0.296

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age ≥ 12 years, n (%)	2 (4.7)	0 (0.0)	1 (3.2)			
SEC low vs. ETA				1.46 [0.07; 89.17] 1.000	1.44 [0.14; 15.20] 1.000	0.01 [-0.07; 0.10] 0.752
SEC high vs. ETA				0.67 [<0.01; 26.28] 0.805	0.23 [0.01; 5.40] 0.403	-0.03 [-0.09; 0.03] 0.309

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.2 Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

S.2.4 Severe Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.5 Adverse Events of Special Interest, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Age < 12 years	13	12	10			
N' Age ≥ 12 years	43	46	31			
Infections and infestations (SOC)						
Interaction test:	p=0.600					
Age < 12 years, n (%)	7 (53.8)	8 (66.7)	5 (50.0)			
SEC low vs. ETA				1.16 [0.17; 8.14] 1.000	1.08 [0.48; 2.39] 1.000	0.04 [-0.37; 0.45] 0.855
SEC high vs. ETA				1.94 [0.26; 15.61] 0.721	1.33 [0.64; 2.79] 0.666	0.17 [-0.24; 0.58] 0.424
Age ≥ 12 years, n (%)	33 (76.7)	31 (67.4)	22 (71.0)			
SEC low vs. ETA				1.34 [0.41; 4.38] 0.766	1.08 [0.82; 1.43] 0.600	0.06 [-0.15; 0.26] 0.578
SEC high vs. ETA				0.85 [0.27; 2.52] 0.940	0.95 [0.70; 1.28] 0.806	-0.04 [-0.25; 0.17] 0.738
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.383					
Age < 12 years, n (%)	1 (7.7)	2 (16.7)	3 (30.0)			
SEC low vs. ETA				0.21 [<0.01; 3.19] 0.400	0.26 [0.03; 2.11] 0.281	-0.22 [-0.54; 0.10] 0.170
SEC high vs. ETA				0.48 [0.03; 5.44] 0.812	0.56 [0.11; 2.70] 0.624	-0.13 [-0.49; 0.22] 0.460
Age ≥ 12 years, n (%)	4 (9.3)	9 (19.6)	2 (6.5)			
SEC low vs. ETA				1.48 [0.20; 17.40] 1.000	1.44 [0.28; 7.38] 1.000	0.03 [-0.09; 0.15] 0.648
SEC high vs. ETA				3.48 [0.65; 35.52] 0.195	3.03 [0.70; 13.10] 0.183	0.13 [-0.01; 0.27] 0.073

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.220					
Age < 12 years, n (%)	2 (15.4)	1 (8.3)	0 (0.0)			
SEC low vs. ETA				1.96 [0.14; >999.99] 0.617	3.93 [0.21; 73.71] 0.486	0.15 [-0.04; 0.35] 0.124
SEC high vs. ETA				0.83 [0.02; >999.99] 1.000	2.54 [0.11; 56.25] 1.000	0.08 [-0.07; 0.24] 0.296
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	1 (3.2)			
SEC low vs. ETA				0.72 [<0.01; 28.12] 0.838	0.24 [0.01; 5.76] 0.419	-0.03 [-0.09; 0.03] 0.309
SEC high vs. ETA				0.67 [<0.01; 26.28] 0.805	0.23 [0.01; 5.40] 0.403	-0.03 [-0.09; 0.03] 0.309
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.6 Tanner Stage, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=1.000**					
Age < 12 years, N / N'	**13 / 13**	**12 / 12**	**10 / 10**			
n (%)	8 (61.5)	2 (16.7)	6 (60.0)			
SEC low vs. ETA				1.06 [0.14; 7.72] 1.000	1.03 [0.53; 1.99] 1.000	0.02 [-0.39; 0.42] 0.940
SEC high vs. ETA				0.15 [0.01; 1.28] 0.096	0.28 [0.07; 1.09] 0.074	-0.43 [-0.80; -0.06] 0.022
Age ≥ 12 years, N / N'	**43 / 43**	**46 / 45**	**31 / 30**			
n (%)	43 (100.0)	40 (88.9)	29 (96.7)			
SEC low vs. ETA				1.43 [0.04; N.E.] 0.822	1.03 [0.97; 1.11] 0.411	0.03 [-0.03; 0.10] 0.309
SEC high vs. ETA				0.28 [<0.01; 2.70] 0.445	0.92 [0.81; 1.04] 0.392	-0.08 [-0.19; 0.03] 0.174
Pubertal at Week 52						
Interaction Test	**p=1.000**					
Age < 12 years, N / N'	**13 / 13**	**12 / 11**	**10 / 7**			
n (%)	10 (76.9)	3 (27.3)	5 (71.4)			
SEC low vs. ETA				1.31 [0.08; 16.01] 1.000	1.08 [0.62; 1.88] 1.000	0.05 [-0.35; 0.46] 0.791
SEC high vs. ETA				0.17 [0.01; 1.74] 0.176	0.38 [0.13; 1.12] 0.145	-0.44 [-0.87; -0.02] 0.042
Age ≥ 12 years, N / N'	**43 / 41**	**46 / 42**	**31 / 29**			
n (%)	41 (100.0)	40 (95.2)	29 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.59 [N.E.; 7.72] 0.693	0.95 [0.89; 1.02] 0.510	-0.05 [-0.11; 0.02] 0.147

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.1 Adverse Events, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Male	20	27	16			
N' Female	36	31	25			
Any AE						
Interaction test:	p=0.007					
Male, n (%)	19 (95.0)	18 (66.7)	13 (81.3)			
SEC low vs. ETA				4.21 [0.30; 242.03] 0.442	1.17 [0.91; 1.51] 0.303	0.14 [-0.08; 0.35] 0.207
SEC high vs. ETA				0.47 [0.07; 2.39] 0.504	0.82 [0.57; 1.17] 0.484	-0.15 [-0.41; 0.12] 0.274
Female, n (%)	27 (75.0)	29 (93.5)	21 (84.0)			
SEC low vs. ETA				0.58 [0.11; 2.43] 0.606	0.89 [0.69; 1.15] 0.530	-0.09 [-0.29; 0.11] 0.382
SEC high vs. ETA				2.71 [0.35; 32.62] 0.475	1.11 [0.92; 1.35] 0.391	0.10 [-0.07; 0.26] 0.265
Any SAE						
Interaction test:	p=0.550					
Male, n (%)	1 (5.0)	2 (7.4)	0 (0.0)			
SEC low vs. ETA				0.80 [0.02; >999.99] 1.000	2.43 [0.11; 55.89] 1.000	0.05 [-0.05; 0.15] 0.305
SEC high vs. ETA				1.46 [0.11; >999.99] 0.777	3.04 [0.15; 59.53] 0.522	0.07 [-0.02; 0.17] 0.142
Female, n (%)	4 (11.1)	3 (9.7)	5 (20.0)			
SEC low vs. ETA				0.51 [0.09; 2.66] 0.546	0.56 [0.17; 1.87] 0.467	-0.09 [-0.28; 0.10] 0.353
SEC high vs. ETA				0.44 [0.06; 2.54] 0.475	0.48 [0.13; 1.83] 0.445	-0.10 [-0.29; 0.08] 0.282

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.216					
Male, n (%)	2 (10.0)	1 (3.7)	1 (6.3)			
SEC low vs. ETA				1.64 [0.08; 104.79] 1.000	1.60 [0.16; 16.10] 1.000	0.04 [-0.14; 0.21] 0.678
SEC high vs. ETA				0.58 [<0.01; 48.28] 1.000	0.59 [0.04; 8.84] 1.000	-0.03 [-0.16; 0.11] 0.718
Female, n (%)	1 (2.8)	4 (12.9)	3 (12.0)			
SEC low vs. ETA				0.21 [<0.01; 2.87] 0.366	0.23 [0.03; 2.10] 0.296	-0.09 [-0.23; 0.05] 0.191
SEC high vs. ETA				1.08 [0.16; 8.20] 1.000	1.08 [0.26; 4.37] 1.000	0.01 [-0.16; 0.18] 0.919
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	1 (3.2)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.81 [0.02; >999.99] 1.000	2.44 [0.10; 57.37] 1.000	0.03 [-0.03; 0.09] 0.309
Any AE leading to study drug discontinuation						
Interaction test:	p=0.241					
Male, n (%)	0 (0.0)	0 (0.0)	1 (6.3)			
SEC low vs. ETA				0.80 [<0.01; 31.20] 0.889	0.27 [0.01; 6.21] 0.444	-0.06 [-0.18; 0.06] 0.302
SEC high vs. ETA				0.59 [<0.01; 23.11] 0.744	0.20 [0.01; 4.69] 0.372	-0.06 [-0.18; 0.06] 0.302

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Female, n (%)	2 (5.6)	1 (3.2)	0 (0.0)			
SEC low vs. ETA				1.71 [0.13; >999.99] 0.689	3.51 [0.18; 70.20] 0.508	0.06 [-0.02; 0.13] 0.146
SEC high vs. ETA				0.81 [0.02; >999.99] 1.000	2.44 [0.10; 57.37] 1.000	0.03 [-0.03; 0.09] 0.309

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.2 Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

S.3.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Male	20	27	16			
N' Female	36	31	25			
Infections and infestations (SOC)						
Interaction test:	p=0.130					
Male, n (%)	17 (85.0)	16 (59.3)	12 (75.0)			
SEC low vs. ETA				1.86 [0.26; 15.09] 0.737	1.13 [0.81; 1.59] 0.675	0.10 [-0.16; 0.36] 0.457
SEC high vs. ETA				0.49 [0.09; 2.23] 0.478	0.79 [0.52; 1.20] 0.342	-0.16 [-0.44; 0.12] 0.273
Female, n (%)	23 (63.9)	23 (74.2)	15 (60.0)			
SEC low vs. ETA				1.18 [0.36; 3.81] 0.965	1.06 [0.71; 1.59] 0.793	0.04 [-0.21; 0.29] 0.759
SEC high vs. ETA				1.89 [0.53; 6.97] 0.399	1.24 [0.84; 1.81] 0.388	0.14 [-0.10; 0.39] 0.258
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=1.000					
Male, n (%)	1 (5.0)	4 (14.8)	1 (6.3)			
SEC low vs. ETA				0.79 [<0.01; 66.06] 1.000	0.80 [0.05; 11.82] 1.000	-0.01 [-0.16; 0.14] 0.872
SEC high vs. ETA				2.56 [0.22; 136.90] 0.751	2.37 [0.29; 19.40] 0.635	0.09 [-0.09; 0.26] 0.348
Female, n (%)	4 (11.1)	7 (22.6)	4 (16.0)			
SEC low vs. ETA				0.66 [0.11; 3.96] 0.852	0.69 [0.19; 2.52] 0.706	-0.05 [-0.23; 0.13] 0.587
SEC high vs. ETA				1.52 [0.33; 8.11] 0.788	1.41 [0.47; 4.28] 0.737	0.07 [-0.14; 0.27] 0.531
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Female, n (%)	2 (5.6)	1 (3.2)	1 (4.0)			
SEC low vs. ETA				1.40 [0.07; 86.71] 1.000	1.39 [0.13; 14.50] 1.000	0.02 [-0.09; 0.12] 0.776
SEC high vs. ETA				0.80 [<0.01; 65.38] 1.000	0.81 [0.05; 12.26] 1.000	-0.01 [-0.11; 0.09] 0.878
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.6 Tanner Stage, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.487**					
Male, N / N'	**20 / 20**	**27 / 27**	**16 / 15**			
n (%)	19 (95.0)	18 (66.7)	12 (80.0)			
SEC low vs. ETA				4.54 [0.32; 262.18] 0.400	1.19 [0.90; 1.56] 0.292	0.15 [-0.07; 0.37] 0.189
SEC high vs. ETA				0.51 [0.07; 2.62] 0.584	0.83 [0.58; 1.20] 0.485	-0.13 [-0.40; 0.14] 0.332
Female, N / N'	**36 / 36**	**31 / 30**	**25 / 25**			
n (%)	32 (88.9)	24 (80.0)	23 (92.0)			
SEC low vs. ETA				0.70 [0.06; 5.37] 1.000	0.97 [0.82; 1.14] 1.000	-0.03 [-0.18; 0.12] 0.680
SEC high vs. ETA				0.35 [0.03; 2.25] 0.386	0.87 [0.70; 1.08] 0.269	-0.12 [-0.30; 0.06] 0.187
Pubertal at Week 52						
Interaction Test	**p=0.309**					
Male, N / N'	**20 / 19**	**27 / 25**	**16 / 13**			
n (%)	19 (100.0)	19 (76.0)	12 (92.3)			
SEC low vs. ETA				1.46 [0.04; N.E.] 0.813	1.08 [0.93; 1.27] 0.406	0.08 [-0.07; 0.22] 0.298
SEC high vs. ETA				0.27 [<0.01; 2.69] 0.441	0.82 [0.63; 1.08] 0.385	-0.16 [-0.38; 0.06] 0.149
Female, N / N'	**36 / 35**	**31 / 28**	**25 / 23**			
n (%)	32 (91.4)	24 (85.7)	22 (95.7)			
SEC low vs. ETA				0.49 [<0.01; 6.57] 0.956	0.96 [0.84; 1.09] 1.000	-0.04 [-0.17; 0.08] 0.507
SEC high vs. ETA				0.28 [<0.01; 3.11] 0.485	0.90 [0.75; 1.07] 0.362	-0.10 [-0.25; 0.05] 0.206

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.1 Adverse Events, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Baseline PASI ≤ Median	27	29	22			
N' Baseline PASI > Median	29	29	19			
Any AE						
Interaction test:	p=0.570					
Baseline PASI ≤ Median, n (%)	24 (88.9)	23 (79.3)	19 (86.4)			
SEC low vs. ETA				1.26 [0.15; 10.49] 1.000	1.03 [0.83; 1.27] 1.000	0.03 [-0.16; 0.21] 0.790
SEC high vs. ETA				0.61 [0.09; 3.34] 0.787	0.92 [0.72; 1.18] 0.714	-0.07 [-0.28; 0.14] 0.501
Baseline PASI > Median, n (%)	22 (75.9)	24 (82.8)	15 (78.9)			
SEC low vs. ETA				0.84 [0.15; 4.04] 1.000	0.96 [0.70; 1.31] 1.000	-0.03 [-0.27; 0.21] 0.802
SEC high vs. ETA				1.27 [0.22; 7.01] 1.000	1.05 [0.79; 1.39] 1.000	0.04 [-0.19; 0.27] 0.744
Any SAE						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	2 (7.4)	2 (6.9)	2 (9.1)			
SEC low vs. ETA				0.80 [0.05; 12.00] 1.000	0.81 [0.12; 5.33] 1.000	-0.02 [-0.17; 0.14] 0.832
SEC high vs. ETA				0.75 [0.05; 11.10] 1.000	0.76 [0.12; 4.97] 1.000	-0.02 [-0.17; 0.13] 0.776
Baseline PASI > Median, n (%)	3 (10.3)	3 (10.3)	3 (15.8)			
SEC low vs. ETA				0.62 [0.07; 5.22] 0.893	0.66 [0.15; 2.91] 0.669	-0.05 [-0.25; 0.14] 0.590
SEC high vs. ETA				0.62 [0.07; 5.22] 0.893	0.66 [0.15; 2.91] 0.669	-0.05 [-0.25; 0.14] 0.590

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.017					
Baseline PASI ≤ Median, n (%)	3 (11.1)	3 (10.3)	0 (0.0)			
SEC low vs. ETA				3.33 [0.34; >999.99] 0.318	5.75 [0.31; 105.71] 0.242	0.11 [-0.01; 0.23] 0.066
SEC high vs. ETA				3.08 [0.32; >999.99] 0.351	5.37 [0.29; 98.81] 0.249	0.10 [-0.01; 0.21] 0.067
Baseline PASI > Median, n (%)	0 (0.0)	2 (6.9)	4 (21.1)			
SEC low vs. ETA				0.11 [<0.01; 0.91] 0.040	0.07 [0.00; 1.30] 0.020	-0.21 [-0.39; -0.03] 0.024
SEC high vs. ETA				0.29 [0.02; 2.26] 0.316	0.33 [0.07; 1.62] 0.197	-0.14 [-0.35; 0.06] 0.176
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	1 (3.4)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.66 [0.02; >999.99] 1.000	2.00 [0.09; 46.68] 1.000	0.03 [-0.03; 0.10] 0.309
Any AE leading to study drug discontinuation						
Interaction test:	p=0.528					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	1 (4.5)			
SEC low vs. ETA				0.81 [<0.01; 31.78] 0.898	0.27 [0.01; 6.41] 0.449	-0.05 [-0.13; 0.04] 0.306
SEC high vs. ETA				0.76 [<0.01; 29.59] 0.863	0.26 [0.01; 5.99] 0.431	-0.05 [-0.13; 0.04] 0.306

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Baseline PASI > Median, n (%)	2 (6.9)	1 (3.4)	0 (0.0)			
SEC low vs. ETA				1.62 [0.12; >999.99] 0.720	3.33 [0.17; 65.84] 0.512	0.07 [-0.02; 0.16] 0.143
SEC high vs. ETA				0.66 [0.02; >999.99] 1.000	2.00 [0.09; 46.68] 1.000	0.03 [-0.03; 0.10] 0.309

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.2 Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

S.4.5 Adverse Events of Special Interest, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Baseline PASI ≤ Median	27	29	22			
N' Baseline PASI > Median	29	29	19			
Infections and infestations (SOC)						
Interaction test:	p=0.306					
Baseline PASI ≤ Median, n (%)	23 (85.2)	20 (69.0)	15 (68.2)			
SEC low vs. ETA				2.63 [0.55; 14.49] 0.283	1.25 [0.90; 1.73] 0.185	0.17 [-0.07; 0.41] 0.158
SEC high vs. ETA				1.04 [0.26; 3.99] 1.000	1.01 [0.69; 1.47] 1.000	0.01 [-0.25; 0.27] 0.952
Baseline PASI > Median, n (%)	17 (58.6)	19 (65.5)	12 (63.2)			
SEC low vs. ETA				0.83 [0.21; 3.14] 0.994	0.93 [0.59; 1.47] 1.000	-0.05 [-0.33; 0.24] 0.752
SEC high vs. ETA				1.11 [0.28; 4.32] 1.000	1.04 [0.67; 1.60] 1.000	0.02 [-0.25; 0.30] 0.868
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.682					
Baseline PASI ≤ Median, n (%)	4 (14.8)	7 (24.1)	3 (13.6)			
SEC low vs. ETA				1.10 [0.16; 8.45] 1.000	1.09 [0.27; 4.35] 1.000	0.01 [-0.18; 0.21] 0.906
SEC high vs. ETA				1.99 [0.38; 13.59] 0.569	1.77 [0.52; 6.08] 0.483	0.11 [-0.11; 0.32] 0.331
Baseline PASI > Median, n (%)	1 (3.4)	4 (13.8)	2 (10.5)			
SEC low vs. ETA				0.31 [<0.01; 6.40] 0.685	0.33 [0.03; 3.37] 0.554	-0.07 [-0.22; 0.08] 0.365
SEC high vs. ETA				1.35 [0.17; 16.52] 1.000	1.31 [0.27; 6.46] 1.000	0.03 [-0.15; 0.22] 0.731

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	1 (3.7)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.81 [0.02; >999.99] 1.000	2.46 [0.11; 57.67] 1.000	0.04 [-0.03; 0.11] 0.308
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	1 (3.4)	1 (3.4)	1 (5.3)			
SEC low vs. ETA				0.65 [<0.01; 53.24] 1.000	0.66 [0.04; 9.85] 1.000	-0.02 [-0.14; 0.10] 0.768
SEC high vs. ETA				0.65 [<0.01; 53.24] 1.000	0.66 [0.04; 9.85] 1.000	-0.02 [-0.14; 0.10] 0.768
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			**Comparison**		
	SEC low (N=56)	**SEC high (N=58)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.6 Tanner Stage, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.494**					
Baseline PASI ≤ Median, N / N'	**27 / 27**	**29 / 28**	**22 / 22**			
n (%)	25 (92.6)	19 (67.9)	20 (90.9)			
SEC low vs. ETA				1.24 [0.08; 18.58] 1.000	1.02 [0.86; 1.21] 1.000	0.02 [-0.14; 0.17] 0.832
SEC high vs. ETA				0.22 [0.02; 1.25] 0.102	0.75 [0.56; 0.99] 0.085	-0.23 [-0.44; -0.02] 0.032
Baseline PASI > Median, N / N'	**29 / 29**	**29 / 29**	**19 / 18**			
n (%)	26 (89.7)	23 (79.3)	15 (83.3)			
SEC low vs. ETA				1.71 [0.20; 14.48] 0.837	1.08 [0.85; 1.37] 0.662	0.06 [-0.14; 0.27] 0.545
SEC high vs. ETA				0.77 [0.11; 4.31] 1.000	0.95 [0.72; 1.26] 1.000	-0.04 [-0.27; 0.19] 0.728
Pubertal at Week 52						
Interaction Test	**p=0.302**					
Baseline PASI ≤ Median, N / N'	**27 / 26**	**29 / 28**	**22 / 20**			
n (%)	24 (92.3)	22 (78.6)	20 (100.0)			
SEC low vs. ETA				0.52 [N.E.; 6.91] 0.628	0.92 [0.83; 1.03] 0.498	-0.08 [-0.18; 0.03] 0.141
SEC high vs. ETA				0.14 [N.E.; 1.08] 0.061	0.79 [0.65; 0.95] 0.034	-0.21 [-0.37; -0.06] 0.006
Baseline PASI > Median, N / N'	**29 / 28**	**29 / 25**	**19 / 16**			
n (%)	27 (96.4)	21 (84.0)	14 (87.5)			
SEC low vs. ETA				3.73 [0.18; 235.79] 0.592	1.10 [0.90; 1.34] 0.543	0.09 [-0.09; 0.27] 0.320
SEC high vs. ETA				0.76 [0.06; 6.13] 1.000	0.96 [0.75; 1.24] 1.000	-0.04 [-0.25; 0.18] 0.751

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.1 Adverse Events, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Europe	39	46	24			
N' Others	17	12	17			
Any AE						
Interaction test:	p=0.128					
Europe, n (%)	33 (84.6)	39 (84.8)	18 (75.0)			
SEC low vs. ETA				1.82 [0.42; 7.93] 0.534	1.13 [0.86; 1.47] 0.510	0.10 [-0.11; 0.30] 0.363
SEC high vs. ETA				1.84 [0.44; 7.47] 0.493	1.13 [0.87; 1.47] 0.346	0.10 [-0.10; 0.30] 0.342
Others, n (%)	13 (76.5)	8 (66.7)	16 (94.1)			
SEC low vs. ETA				0.21 [<0.01; 2.50] 0.335	0.81 [0.61; 1.09] 0.335	-0.18 [-0.41; 0.05] 0.134
SEC high vs. ETA				0.13 [<0.01; 1.65] 0.155	0.71 [0.47; 1.08] 0.130	-0.27 [-0.56; 0.01] 0.063
Any SAE						
Interaction test:	p=1.000					
Europe, n (%)	4 (10.3)	4 (8.7)	4 (16.7)			
SEC low vs. ETA				0.58 [0.10; 3.46] 0.711	0.62 [0.17; 2.23] 0.467	-0.06 [-0.24; 0.11] 0.478
SEC high vs. ETA				0.48 [0.08; 2.87] 0.537	0.52 [0.14; 1.91] 0.432	-0.08 [-0.25; 0.09] 0.358
Others, n (%)	1 (5.9)	1 (8.3)	1 (5.9)			
SEC low vs. ETA				1.00 [0.01; 83.34] 1.000	1.00 [0.07; 14.72] 1.000	0.00 [-0.16; 0.16] 1.000
SEC high vs. ETA				1.44 [0.02; 121.21] 1.000	1.42 [0.10; 20.49] 1.000	0.02 [-0.17; 0.22] 0.803

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.454					
Europe, n (%)	3 (7.7)	3 (6.5)	2 (8.3)			
SEC low vs. ETA				0.92 [0.10; 11.80] 1.000	0.92 [0.17; 5.13] 1.000	-0.01 [-0.15; 0.13] 0.928
SEC high vs. ETA				0.77 [0.08; 9.86] 1.000	0.78 [0.14; 4.37] 1.000	-0.02 [-0.15; 0.11] 0.787
Others, n (%)	0 (0.0)	2 (16.7)	2 (11.8)			
SEC low vs. ETA				0.40 [<0.01; 5.27] 0.485	0.20 [0.01; 3.88] 0.485	-0.12 [-0.27; 0.04] 0.132
SEC high vs. ETA				1.48 [0.09; 23.59] 1.000	1.42 [0.23; 8.70] 1.000	0.05 [-0.21; 0.31] 0.712
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	1 (2.2)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.52 [0.01; >999.99] 1.000	1.60 [0.07; 37.75] 1.000	0.02 [-0.02; 0.06] 0.312
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=1.000					
Europe, n (%)	1 (2.6)	1 (2.2)	1 (4.2)			
SEC low vs. ETA				0.61 [<0.01; 49.56] 1.000	0.62 [0.04; 9.39] 1.000	-0.02 [-0.11; 0.08] 0.739
SEC high vs. ETA				0.52 [<0.01; 41.85] 1.000	0.52 [0.03; 7.98] 1.000	-0.02 [-0.11; 0.07] 0.666

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Others, n (%)	1 (5.9)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.00 [0.03; >999.99] 1.000	3.00 [0.13; 68.85] 1.000	0.06 [-0.05; 0.17] 0.303
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.2 Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.5 Adverse Events of Special Interest, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Europe	39	46	24			
N' Others	17	12	17			
Infections and infestations (SOC)						
Interaction test:	p=0.413					
Europe, n (%)	29 (74.4)	34 (73.9)	16 (66.7)			
SEC low vs. ETA				1.44 [0.41; 5.04] 0.706	1.12 [0.80; 1.56] 0.573	0.08 [-0.16; 0.31] 0.518
SEC high vs. ETA				1.41 [0.41; 4.67] 0.712	1.11 [0.80; 1.54] 0.583	0.07 [-0.15; 0.30] 0.532
Others, n (%)	11 (64.7)	5 (41.7)	11 (64.7)			
SEC low vs. ETA				1.00 [0.20; 5.11] 1.000	1.00 [0.61; 1.64] 1.000	0.00 [-0.32; 0.32] 1.000
SEC high vs. ETA				0.40 [0.07; 2.25] 0.396	0.64 [0.30; 1.37] 0.274	-0.23 [-0.59; 0.13] 0.209
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.415					
Europe, n (%)	3 (7.7)	10 (21.7)	2 (8.3)			
SEC low vs. ETA				0.92 [0.10; 11.80] 1.000	0.92 [0.17; 5.13] 1.000	-0.01 [-0.15; 0.13] 0.928
SEC high vs. ETA				3.01 [0.56; 30.82] 0.279	2.61 [0.62; 10.96] 0.197	0.13 [-0.03; 0.30] 0.106
Others, n (%)	2 (11.8)	1 (8.3)	3 (17.6)			
SEC low vs. ETA				0.63 [0.05; 6.39] 1.000	0.67 [0.13; 3.50] 1.000	-0.06 [-0.30; 0.18] 0.627
SEC high vs. ETA				0.44 [<0.01; 6.34] 0.888	0.47 [0.06; 4.01] 0.622	-0.09 [-0.33; 0.15] 0.446

S.5.5 Adverse Events of Special Interest, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	2 (5.1)	1 (2.2)	1 (4.2)			
SEC low vs. ETA				1.24 [0.06; 76.49] 1.000	1.23 [0.12; 12.85] 1.000	0.01 [-0.10; 0.12] 0.859
SEC high vs. ETA				0.52 [<0.01; 41.85] 1.000	0.52 [0.03; 7.98] 1.000	-0.02 [-0.11; 0.07] 0.666
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.6 Tanner Stage, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.818**					
Europe, N / N'	**39 / 39**	**46 / 46**	**24 / 24**			
n (%)	36 (92.3)	37 (80.4)	22 (91.7)			
SEC low vs. ETA				1.09 [0.08; 10.31] 1.000	1.01 [0.87; 1.17] 1.000	0.01 [-0.13; 0.15] 0.928
SEC high vs. ETA				0.38 [0.04; 2.07] 0.384	0.88 [0.73; 1.06] 0.309	-0.11 [-0.27; 0.05] 0.167
Others, N / N'	**17 / 17**	**12 / 11**	**17 / 16**			
n (%)	15 (88.2)	5 (45.5)	13 (81.3)			
SEC low vs. ETA				1.70 [0.17; 23.37] 0.939	1.09 [0.81; 1.45] 0.656	0.07 [-0.18; 0.31] 0.576
SEC high vs. ETA				0.21 [0.02; 1.41] 0.128	0.56 [0.28; 1.11] 0.097	-0.36 [-0.71; -0.01] 0.046
Pubertal at Week 52						
Interaction Test	**p=0.212**					
Europe, N / N'	**39 / 39**	**46 / 42**	**24 / 23**			
n (%)	36 (92.3)	37 (88.1)	22 (95.7)			
SEC low vs. ETA				0.55 [<0.01; 7.35] 1.000	0.97 [0.85; 1.09] 1.000	-0.03 [-0.15; 0.08] 0.579
SEC high vs. ETA				0.34 [<0.01; 3.34] 0.601	0.92 [0.80; 1.06] 0.411	-0.08 [-0.20; 0.05] 0.249
Others, N / N'	**17 / 15**	**12 / 11**	**17 / 13**			
n (%)	15 (100.0)	6 (54.5)	12 (92.3)			
SEC low vs. ETA				1.15 [0.03; N.E.] 0.929	1.08 [0.93; 1.27] 0.464	0.08 [-0.07; 0.22] 0.298
SEC high vs. ETA				0.11 [<0.01; 1.30] 0.096	0.59 [0.34; 1.04] 0.061	-0.38 [-0.71; -0.05] 0.024

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.1 Adverse Events, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Weight < 50 kg	28	26	20			
N' Weight ≥ 50 kg	28	32	21			
Any AE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	22 (78.6)	20 (76.9)	16 (80.0)			
SEC low vs. ETA				0.92 [0.16; 4.64] 1.000	0.98 [0.73; 1.32] 1.000	-0.01 [-0.25; 0.22] 0.904
SEC high vs. ETA				0.84 [0.15; 4.26] 1.000	0.96 [0.71; 1.30] 1.000	-0.03 [-0.27; 0.21] 0.801
Weight ≥ 50 kg, n (%)	24 (85.7)	27 (84.4)	18 (85.7)			
SEC low vs. ETA				1.00 [0.13; 6.74] 1.000	1.00 [0.79; 1.26] 1.000	0.00 [-0.20; 0.20] 1.000
SEC high vs. ETA				0.90 [0.12; 5.33] 1.000	0.98 [0.78; 1.24] 1.000	-0.01 [-0.21; 0.18] 0.893
Any SAE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	2 (7.1)	2 (7.7)	2 (10.0)			
SEC low vs. ETA				0.70 [0.05; 10.45] 1.000	0.71 [0.11; 4.65] 1.000	-0.03 [-0.19; 0.13] 0.730
SEC high vs. ETA				0.75 [0.05; 11.34] 1.000	0.77 [0.12; 5.00] 1.000	-0.02 [-0.19; 0.14] 0.786
Weight ≥ 50 kg, n (%)	3 (10.7)	3 (9.4)	3 (14.3)			
SEC low vs. ETA				0.72 [0.09; 6.05] 1.000	0.75 [0.17; 3.35] 1.000	-0.04 [-0.22; 0.15] 0.710
SEC high vs. ETA				0.63 [0.08; 5.20] 0.895	0.66 [0.15; 2.95] 0.671	-0.05 [-0.23; 0.13] 0.594

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.238					
Weight < 50 kg, n (%)	0 (0.0)	3 (11.5)	2 (10.0)			
SEC low vs. ETA				0.28 [<0.01; 3.75] 0.337	0.14 [0.01; 2.86] 0.168	-0.10 [-0.23; 0.03] 0.136
SEC high vs. ETA				1.17 [0.12; 15.41] 1.000	1.15 [0.21; 6.26] 1.000	0.02 [-0.16; 0.20] 0.867
Weight ≥ 50 kg, n (%)	3 (10.7)	2 (6.3)	2 (9.5)			
SEC low vs. ETA				1.14 [0.12; 14.89] 1.000	1.13 [0.21; 6.14] 1.000	0.01 [-0.16; 0.18] 0.891
SEC high vs. ETA				0.64 [0.04; 9.51] 1.000	0.66 [0.10; 4.31] 1.000	-0.03 [-0.18; 0.12] 0.671
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	1 (3.8)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.77 [0.02; >999.99] 1.000	2.33 [0.10; 54.42] 1.000	0.04 [-0.04; 0.11] 0.308
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.637					
Weight < 50 kg, n (%)	1 (3.6)	1 (3.8)	0 (0.0)			
SEC low vs. ETA				0.71 [0.02; >999.99] 1.000	2.17 [0.09; 50.75] 1.000	0.04 [-0.03; 0.10] 0.309
SEC high vs. ETA				0.77 [0.02; >999.99] 1.000	2.33 [0.10; 54.42] 1.000	0.04 [-0.04; 0.11] 0.308

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Weight ≥ 50 kg, n (%)	1 (3.6)	0 (0.0)	1 (4.8)			
SEC low vs. ETA				0.75 [<0.01; 61.02] 1.000	0.75 [0.05; 11.31] 1.000	-0.01 [-0.13; 0.10] 0.838
SEC high vs. ETA				0.66 [<0.01; 25.59] 0.792	0.22 [0.01; 5.21] 0.396	-0.05 [-0.14; 0.04] 0.306

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.2 Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

S.6.4 Severe Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.5 Adverse Events of Special Interest, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' Weight < 50 kg	28	26	20			
N' Weight ≥ 50 kg	28	32	21			
Infections and infestations (SOC)						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	18 (64.3)	16 (61.5)	12 (60.0)			
SEC low vs. ETA				1.20 [0.31; 4.56] 0.997	1.07 [0.68; 1.68] 0.772	0.04 [-0.24; 0.32] 0.763
SEC high vs. ETA				1.07 [0.27; 4.11] 1.000	1.03 [0.64; 1.64] 1.000	0.02 [-0.27; 0.30] 0.916
Weight ≥ 50 kg, n (%)	22 (78.6)	23 (71.9)	15 (71.4)			
SEC low vs. ETA				1.46 [0.32; 6.65] 0.805	1.10 [0.79; 1.53] 0.739	0.07 [-0.17; 0.32] 0.569
SEC high vs. ETA				1.02 [0.24; 4.03] 1.000	1.01 [0.71; 1.42] 1.000	0.00 [-0.24; 0.25] 0.972
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.694					
Weight < 50 kg, n (%)	2 (7.1)	6 (23.1)	3 (15.0)			
SEC low vs. ETA				0.44 [0.03; 4.30] 0.680	0.48 [0.09; 2.59] 0.636	-0.08 [-0.26; 0.10] 0.401
SEC high vs. ETA				1.68 [0.30; 11.97] 0.766	1.54 [0.44; 5.41] 0.711	0.08 [-0.14; 0.31] 0.482
Weight ≥ 50 kg, n (%)	3 (10.7)	5 (15.6)	2 (9.5)			
SEC low vs. ETA				1.14 [0.12; 14.89] 1.000	1.13 [0.21; 6.14] 1.000	0.01 [-0.16; 0.18] 0.891
SEC high vs. ETA				1.74 [0.25; 20.12] 0.839	1.64 [0.35; 7.69] 0.690	0.06 [-0.12; 0.24] 0.501

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.241					
Weight < 50 kg, n (%)	2 (7.1)	1 (3.8)	0 (0.0)			
SEC low vs. ETA				1.77 [0.13; >999.99] 0.670	3.62 [0.18; 71.57] 0.504	0.07 [-0.02; 0.17] 0.142
SEC high vs. ETA				0.77 [0.02; >999.99] 1.000	2.33 [0.10; 54.42] 1.000	0.04 [-0.04; 0.11] 0.308
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	1 (4.8)			
SEC low vs. ETA				0.75 [<0.01; 29.25] 0.857	0.25 [0.01; 5.91] 0.429	-0.05 [-0.14; 0.04] 0.306
SEC high vs. ETA				0.66 [<0.01; 25.59] 0.792	0.22 [0.01; 5.21] 0.396	-0.05 [-0.14; 0.04] 0.306
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.6 Tanner Stage, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.444**					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 25**	**20 / 19**			
n (%)	23 (82.1)	11 (44.0)	15 (78.9)			
SEC low vs. ETA				1.22 [0.21; 6.74] 1.000	1.04 [0.78; 1.39] 1.000	0.03 [-0.20; 0.26] 0.787
SEC high vs. ETA				0.22 [0.04; 0.95] 0.040	0.56 [0.34; 0.92] 0.030	-0.35 [-0.62; -0.08] 0.010
Weight ≥ 50 kg, N / N'	**28 / 28**	**32 / 32**	**21 / 21**			
n (%)	28 (100.0)	31 (96.9)	20 (95.2)			
SEC low vs. ETA				1.33 [0.03; N.E.] 0.857	1.05 [0.95; 1.16] 0.429	0.05 [-0.04; 0.14] 0.306
SEC high vs. ETA				1.54 [0.02; 125.53] 1.000	1.02 [0.91; 1.14] 1.000	0.02 [-0.09; 0.13] 0.769
Pubertal at Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**28 / 28**	**26 / 23**	**20 / 17**			
n (%)	25 (89.3)	13 (56.5)	15 (88.2)			
SEC low vs. ETA				1.11 [0.08; 10.88] 1.000	1.01 [0.82; 1.26] 1.000	0.01 [-0.18; 0.20] 0.914
SEC high vs. ETA				0.18 [0.02; 1.08] 0.064	0.64 [0.43; 0.95] 0.041	-0.32 [-0.57; -0.06] 0.014
Weight ≥ 50 kg, N / N'	**28 / 26**	**32 / 30**	**21 / 19**			
n (%)	26 (100.0)	30 (100.0)	19 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.1 Adverse Events, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' No previous systemic therapy	23	26	22			
N' Previous systemic therapy	33	32	19			
Any AE						
Interaction test:	p=0.083					
No previous systemic therapy, n (%)	20 (87.0)	23 (88.5)	16 (72.7)			
SEC low vs. ETA				2.45 [0.44; 17.54] 0.413	1.20 [0.88; 1.62] 0.284	0.14 [-0.09; 0.37] 0.228
SEC high vs. ETA				2.81 [0.51; 19.97] 0.308	1.22 [0.91; 1.63] 0.267	0.16 [-0.07; 0.38] 0.167
Previous systemic therapy, n (%)	26 (78.8)	24 (75.0)	18 (94.7)			
SEC low vs. ETA				0.21 [<0.01; 1.88] 0.253	0.83 [0.68; 1.02] 0.232	-0.16 [-0.33; 0.01] 0.069
SEC high vs. ETA				0.17 [<0.01; 1.48] 0.150	0.79 [0.63; 0.99] 0.128	-0.20 [-0.38; -0.02] 0.032
Any SAE						
Interaction test:	p=0.249					
No previous systemic therapy, n (%)	3 (13.0)	2 (7.7)	1 (4.5)			
SEC low vs. ETA				3.08 [0.23; 173.09] 0.642	2.87 [0.32; 25.55] 0.608	0.08 [-0.08; 0.25] 0.306
SEC high vs. ETA				1.73 [0.08; 108.09] 1.000	1.69 [0.16; 17.44] 1.000	0.03 [-0.10; 0.17] 0.646
Previous systemic therapy, n (%)	2 (6.1)	3 (9.4)	4 (21.1)			
SEC low vs. ETA				0.25 [0.02; 1.96] 0.241	0.29 [0.06; 1.43] 0.175	-0.15 [-0.35; 0.05] 0.143
SEC high vs. ETA				0.40 [0.05; 2.67] 0.448	0.45 [0.11; 1.78] 0.402	-0.12 [-0.33; 0.09] 0.274

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.388					
No previous systemic therapy, n (%)	2 (8.7)	2 (7.7)	1 (4.5)			
SEC low vs. ETA				1.97 [0.10; 123.52] 1.000	1.91 [0.19; 19.63] 1.000	0.04 [-0.10; 0.19] 0.573
SEC high vs. ETA				1.73 [0.08; 108.09] 1.000	1.69 [0.16; 17.44] 1.000	0.03 [-0.10; 0.17] 0.646
Previous systemic therapy, n (%)	1 (3.0)	3 (9.4)	3 (15.8)			
SEC low vs. ETA				0.17 [<0.01; 2.35] 0.265	0.19 [0.02; 1.72] 0.132	-0.13 [-0.30; 0.05] 0.151
SEC high vs. ETA				0.56 [0.07; 4.67] 0.792	0.59 [0.13; 2.65] 0.659	-0.06 [-0.26; 0.13] 0.514
Any AE leading to study discontinuation						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	1 (3.8)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.85 [0.02; >999.99] 1.000	2.56 [0.11; 59.75] 1.000	0.04 [-0.04; 0.11] 0.308
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.609					
No previous systemic therapy, n (%)	1 (4.3)	1 (3.8)	0 (0.0)			
SEC low vs. ETA				0.96 [0.02; >999.99] 1.000	2.88 [0.12; 67.03] 1.000	0.04 [-0.04; 0.13] 0.307
SEC high vs. ETA				0.85 [0.02; >999.99] 1.000	2.56 [0.11; 59.75] 1.000	0.04 [-0.04; 0.11] 0.308

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Previous systemic therapy, n (%)	1 (3.0)	0 (0.0)	1 (5.3)			
SEC low vs. ETA				0.57 [<0.01; 46.58] 1.000	0.58 [0.04; 8.69] 1.000	-0.02 [-0.14; 0.09] 0.706
SEC high vs. ETA				0.59 [<0.01; 23.16] 0.745	0.20 [0.01; 4.72] 0.373	-0.05 [-0.15; 0.05] 0.304

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.2 Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.2 Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

S.7.3 Serious Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.4 Severe Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.5 Adverse Events of Special Interest, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	56	58	41			
N' No previous systemic therapy	23	26	22			
N' Previous systemic therapy	33	32	19			
Infections and infestations (SOC)						
Interaction test:	p=0.551					
No previous systemic therapy, n (%)	18 (78.3)	20 (76.9)	14 (63.6)			
SEC low vs. ETA				2.02 [0.46; 9.76] 0.452	1.23 [0.84; 1.80] 0.337	0.15 [-0.12; 0.41] 0.275
SEC high vs. ETA				1.88 [0.45; 8.21] 0.490	1.21 [0.83; 1.77] 0.355	0.13 [-0.13; 0.39] 0.313
Previous systemic therapy, n (%)	22 (66.7)	19 (59.4)	13 (68.4)			
SEC low vs. ETA				0.92 [0.22; 3.56] 1.000	0.97 [0.66; 1.44] 1.000	-0.02 [-0.28; 0.25] 0.896
SEC high vs. ETA				0.68 [0.17; 2.56] 0.734	0.87 [0.57; 1.32] 0.564	-0.09 [-0.36; 0.18] 0.511
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.596					
No previous systemic therapy, n (%)	3 (13.0)	4 (15.4)	3 (13.6)			
SEC low vs. ETA				0.95 [0.11; 8.01] 1.000	0.96 [0.22; 4.24] 1.000	-0.01 [-0.20; 0.19] 0.953
SEC high vs. ETA				1.15 [0.17; 8.85] 1.000	1.13 [0.28; 4.51] 1.000	0.02 [-0.18; 0.22] 0.864
Previous systemic therapy, n (%)	2 (6.1)	7 (21.9)	2 (10.5)			
SEC low vs. ETA				0.56 [0.04; 8.29] 0.932	0.58 [0.09; 3.76] 0.617	-0.04 [-0.20; 0.12] 0.585
SEC high vs. ETA				2.34 [0.38; 25.80] 0.528	2.08 [0.48; 9.00] 0.455	0.11 [-0.09; 0.31] 0.263

	Treatment Groups			Comparison		
	SEC low (N=56)	**SEC high (N=58)**	**ETA (N=41)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=1.000					
No previous systemic therapy, n (%)	1 (4.3)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.96 [0.02; >999.99] 1.000	2.88 [0.12; 67.03] 1.000	0.04 [-0.04; 0.13] 0.307
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	1 (3.0)	1 (3.1)	1 (5.3)			
SEC low vs. ETA				0.57 [<0.01; 46.58] 1.000	0.58 [0.04; 8.69] 1.000	-0.02 [-0.14; 0.09] 0.706
SEC high vs. ETA				0.59 [<0.01; 48.09] 1.000	0.59 [0.04; 8.95] 1.000	-0.02 [-0.14; 0.10] 0.720
Drug specific antibody present (PT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

| | Treatment Groups | | | Comparison | | |
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

## S.7.6 Tanner Stage, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.848**					
No previous systemic therapy, N / N'	**23 / 23**	**26 / 26**	**22 / 21**			
n (%)	21 (91.3)	20 (76.9)	18 (85.7)			
SEC low vs. ETA				1.73 [0.18; 22.85] 0.911	1.07 [0.86; 1.32] 0.658	0.06 [-0.13; 0.24] 0.562
SEC high vs. ETA				0.56 [0.08; 3.11] 0.705	0.90 [0.68; 1.18] 0.711	-0.09 [-0.31; 0.13] 0.435
Previous systemic therapy, N / N'	**33 / 33**	**32 / 31**	**19 / 19**			
n (%)	30 (90.9)	22 (71.0)	17 (89.5)			
SEC low vs. ETA				1.17 [0.09; 11.33] 1.000	1.02 [0.84; 1.23] 1.000	0.01 [-0.15; 0.18] 0.868
SEC high vs. ETA				0.29 [0.03; 1.70] 0.234	0.79 [0.60; 1.04] 0.170	-0.19 [-0.40; 0.03] 0.086
Pubertal at Week 52						
Interaction Test	**p=0.367**					
No previous systemic therapy, N / N'	**23 / 22**	**26 / 23**	**22 / 18**			
n (%)	20 (90.9)	21 (91.3)	17 (94.4)			
SEC low vs. ETA				0.60 [<0.01; 12.39] 1.000	0.96 [0.81; 1.14] 1.000	-0.04 [-0.20; 0.12] 0.665
SEC high vs. ETA				0.62 [<0.01; 12.97] 1.000	0.97 [0.82; 1.14] 1.000	-0.03 [-0.19; 0.12] 0.694
Previous systemic therapy, N / N'	**33 / 32**	**32 / 30**	**19 / 18**			
n (%)	31 (96.9)	22 (73.3)	17 (94.4)			
SEC low vs. ETA				1.80 [0.02; 147.68] 1.000	1.03 [0.90; 1.17] 1.000	0.02 [-0.10; 0.15] 0.696
SEC high vs. ETA				0.17 [<0.01; 1.45] 0.143	0.78 [0.61; 0.99] 0.125	-0.21 [-0.40; -0.02] 0.030

	Treatment Groups			Comparison		
	SEC low (N=56)	SEC high (N=58)	ETA (N=41)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

Figures

Efficacy Analysis

8.1 CDLQI, Boxplot (FAS)

### 8.3 CDLQI, Boxplot by Gender (FAS)

Male

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

Female

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

9.1 CDLQI (Age ≤ 16), Boxplot (FAS)